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1. Introduction
This report describes the results of the 20th 
proficiency test organised by the Technical 
University of Denmark, National Food Institute 
(DTU-FOOD) as the EU Reference Laboratory 
for Antimicrobial Resistance (EURL-AR). This 
proficiency test focuses on antimicrobial 
susceptibility testing (AST) of enterococci, 
staphylococci and Escherichia coli. It is the 
tenth External Quality Assurance System 
(EQAS) conducted for AST of these 
microorganisms. 
The aim of this EQAS is to: i) monitor the 
quality of AST results produced by National 
Reference Laboratories (NRL-AR), ii) identify 
laboratories which may need assistance to 
improve their performance in AST, and iii) 
determine possible topics for future research 
and collaboration. 
When reading this report, please consider: 
1) Expected results were generated by
performing Minimum Inhibitory Concentration
(MIC) determination on two occasions at DTU-
FOOD. These results were verified by the
United States Food and Drug Administration
(FDA), Centre for Veterinary Medicine. Finally,
MIC determination was performed at DTU-
FOOD after preparation of the agar stab
cultures to be shipped to participants to confirm
that the vials contained the correct strains with
the expected MIC values.
2) The evaluation is based on interpretation of
MIC values in agreement with the method
reported in Decision 2013/652/EU for testing of
E. coli and enterococci.  For AST of 
staphylococci, it is recommended to implement 
the most recent recommendations from EFSA. 
Participants were requested to apply the same 
method used when generating AST results to 
be reported to EFSA. This request was made to 
ensure compliance with the main objective of 
this EQAS “to assess and improve the 
comparability of antimicrobial susceptibility data 
reported to EFSA by the different NRLs”, as 
stated in the protocol (Appendix 4). 
3) Only results obtained by MIC determination
methods were allowed in this EQAS to comply
with Decision 2013/652/EU. Thus, the set-up of
the database for reporting results did not allow
upload of disk diffusion results.
4) Laboratory performance is considered
acceptable if there are < 5% deviations from
expected results, as previously agreed by the
EURL-AR network.
Evaluation of a result as “deviating from the 
expected interpretation” should be carefully 
analysed in a self-evaluation procedure 
performed by individual participants when the 
EQAS trial results are disclosed. MIC 
determination methods have limitations in 
reproducibility, thus a one-fold dilution 
difference in the MIC of a specific antimicrobial 
could occur even when testing the same strain. 
If the expected MIC is close to the breakpoint 
value for categorising the strain as susceptible 
or resistant, a one-fold dilution difference may 
result in different interpretations. Since this 
report evaluates the interpretations of MIC 
values, some participants may find their results 
classified as wrong even though the actual MIC 
measured is only one-fold dilution different from 
the expected MIC. In these cases (hereafter 
defined “one-fold dilution issues”), the 
participants should be confident about the good 
quality of their AST performance. At the EURL-
AR, we strive to select test strains with MIC 
values distant from the breakpoints for 
resistance to avoid these ambiguous situations, 
though this is not always feasible for all strains 
and antimicrobial combinations. For this reason, 
the EURL-AR network unanimously established 
in 2008 that, if there are less than 75% correct 
results for a specific strain/antimicrobial 
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combination, these results may be subtracted 
from the evaluation report after a case by case 
evaluation to be detailed in the report. 
This report is approved in its final version by a 
technical advisory group composed by 
competent representatives from all NRLs who 
meet yearly at the EURL-AR workshop. 
All conclusions presented in this report are 
publicly available. However, participating 
laboratories are identified by codes and each 
code is known only by the corresponding 
laboratory. The full list of laboratory codes is 
confidential information known only by relevant 
representatives of the EURL-AR and the EU 
Commission.  
The EURL-AR is accredited by DANAK as 
provider of proficiency testing (accreditation no. 
516); working with zoonotic pathogens and 
indicator organisms as bacterial isolates 
(identification, serotyping and antimicrobial 
susceptibility testing). 
2. Materials and Methods
2.1 Participants in EQAS 2016 
A pre-notification to announce the EQAS 2016 
on AST of enterococci, staphylococci and E. 
coli was sent by e-mail on the 8th March 2016 to 
the designated NRL-AR in the network 
(Appendix 1) and to eight additional laboratories 
(Denmark, Iceland, Norway, Serbia, Spain, 
Switzerland, the Netherlands, Turkey and 
United Kingdom) invited to participate based on 
participation to previous EQAS iterations and/or 
affiliation to the EU network. 
Participating laboratories represented all 28 EU 
Member States (MS) and three non-MS 
(Iceland, Norway, and Switzerland; Appendix 2 
and Figure 1). Only one set of data per MS is 
included in this report. 
2.2 Strains  
The eight enterococci, eight staphylococci and 
eight E. coli included in this EQAS were 
selected among the DTU-FOOD strain 
collection based on available MIC data. For 
quality assurance purposes, one strain per 
each bacterial species has been included in all 
Figure 1. Countries participating in the EURL-AR EQAS on antimicrobial susceptibility testing of enterococci, 
staphylococci and/or Escherichia coli, 2016
Participants
Not participants
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EQAS iterations performed to date to represent 
an internal control. 
Expected MIC values (Appendix 3) for this 
EQAS were generated by using Sensititre 
panels (Trek Diagnostic Systems) at DTU-
FOOD and further verified by the U.S. FDA. 
Results could not be verified by FDA for: 
ampicillin and teicoplanin (enterococci); colistin, 
ertapenem, meropenem, temocillin and 
tigecycline (E. coli); and sulfamethoxazole, 
tiamulin and trimethoprim (staphylococci). MICs 
were further determined at DTU-FOOD after 
production of agar stab cultures to confirm 
expected values prior to shipment and to 
ensure homogeneity of the test cultures at the 
DTU-FOOD laboratory. 
Reference strains Enterococcus faecalis ATCC 
29212, Staphylococcus aureus ATCC 29213 
and E. coli ATCC 25922 were provided to new 
participants with instructions to store and 
maintain them for quality assurance purposes 
and future EQAS trials. The expected quality 
control ranges for the reference strains were 
retrieved from Clinical and Laboratory 
Standards Institute (CLSI) in documents VET01 
A4 (2013) / M100-S26 (2016) (App. 5).  
 
2.3 Antimicrobials  
The panels of antimicrobials recommended for 
AST in this trial are listed in Table 1. 
These antimicrobials represent those defined 
by the Commission Implementing Decision 
2013/652/EU for E. coli and enterococci, and 




The bacterial strains were dispatched as agar 
stab cultures on 28th June 2016. These 
Table 1. Panels of antimicrobials for antimicrobial susceptibility testing included in this EURL-AR EQAS 2016 component 
Enterococci  Staphylococci  Escherichia coli  1st panel 
Escherichia coli  
2nd panel 
Ampicillin, AMP  Cefoxitin, FOX  Ampicillin, AMP  Cefepime, FEP  
Chloramphenicol, CHL  Chloramphenicol, CHL Azithromycin, AZI  Cefotaxime + 
clavulanic acid (F/C)  
Ciprofloxacin, CIP  Ciprofloxacin, CIP Cefotaxime, FOT  Cefotaxime, FOT  
Daptomycin, DAP  Clindamycin, CLN Ceftazidime, TAZ  Cefoxitin, FOX 
Erythromycin, ERY  Erythromycin, ERY  Chloramphenicol, CHL  Ceftazidime, TAZ  
Gentamicin, GEN  Gentamicin, GEN Ciprofloxacin, CIP  Ceftazidime+ 
clavulanic acid (T/C)  
Linezolid, LZD  Linezolid, LZD Colistin, COL  Ertapenem, ETP  
Quinupristin-dalfopristin 
(Synercid), SYN  
Mupirocin, MUP Gentamicin, GEN  Imipenem, IMI  
Teicoplanin, TEI  Quinupristin-dalfopristin (Synercid), 
SYN  
Meropenem, MERO  Meropenem, MERO  
Tetracycline, TET  Sulfamethoxazole, SMX  Nalidixic acid, NAL  Temocillin, TRM 
Tigecycline, TGC  Sulfamethoxazole+Trimethoprim, SXT  Sulfamethoxazole, SMX   
Vancomycin, VAN Tetracycline, TET  Tetracycline, TET   
 Tiamulin, TIA  Tigecycline, TGC   
 Trimethoprim, TMP  Trimethoprim, TMP  
 Vancomycin, VAN   
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bacterial cultures were shipped in double pack 
containers (class UN 6.2) as UN3373, biological 
substances category B according to the 
International Air Transport Association (IATA) 
regulations. 
2.5 Procedure 
The participants were recommended to keep 
the agar stab cultures refrigerated until 
performance of AST. Protocols and all relevant 
information were uploaded on the EURL-AR 
website (http://www.eurl-ar.eu) thus being 
available at any time (Appendix 4). Guidelines 
for performing AST were set according to the 
CLSI document – M7-A10 (2015) “Methods for 
Dilution Antimicrobial Susceptibility Tests for 
Bacteria That Grow Aerobically; Approved 
Standard - 10th Edition”. Manufacturer’s 
guidelines had to be followed when commercial 
methods were used.  
Instructions for interpretation of AST results 
adhered to those specified in the Commission 
Implementing Decision 2013/652/EU, and were 
provided in the protocol (Appendix 4b: Tables 1, 
2 and 3).  Participants were invited to 
categorise the strains as resistant or 
susceptible using EUCAST epidemiological cut-
off (ECOFF) values (www.eucast.org). For 
interpretation of the results of the E. coli 2nd 
panel (to be tested when a strain displayed 
resistance to cefotaxime, ceftazidime and/or 
meropenem in the E. coli 1st panel) participants 
were invited to adhere to recommendations by 
EFSA (Appendix 4b). 
The EURL-AR is aware that there are two types 
of criteria for interpretation of MIC results: 
clinical breakpoints and ECOFF values. The 
terms ‘susceptible’, ‘intermediate’ and ‘resistant’ 
should be used for classification made in 
relation to the therapeutic application of 
antimicrobial agents, whereas bacteria should 
be reported as ‘wild-type’ or ‘non-wild-type’ 
when reporting data relative to ECOFF values 
(Schwarz et al., 2010). To simplify the 
interpretation of results, we maintain the terms 
susceptible and resistant throughout this report 
even when referring to wild-type and non-wild-
type strains. 
All participants were invited to enter the 
obtained results into an electronic record sheet 
at the EURL-AR web-based database designed 
for this trial. Participants were also encouraged 
to complete an evaluation form available on the 
EURL-AR database with the aim to improve 
future EQAS trials. 
The database could be accessed through a 
secured individual login and password.  
The database was closed on 5th September 
2015. 
After this date, the participants were invited to 
login again to retrieve an individual database-
generated evaluation report.  
3. Results and Discussion
In this report, results from 28, 27 and 31 
laboratories for enterococci, staphylococci and 
E. coli were evaluated, respectively. The
participants were invited to report MIC values
and categorisation as resistant or susceptible
for each strain/antimicrobial combination. Only
the categorisation was evaluated, whereas the
MIC values were used as supplementary
information.
3.1 Results excluded from the 
report 
The following strain/antimicrobial combinations 
resulted in > 25% deviations from expected 
results: ENT-10.7/chloramphenicol, ST-
10.4/ciprofloxacin, ST-10.8/ciprofloxacin and 
EC-10.8/ertapenem.  In agreement with the 
decision by the EURL-AR network these results 
were carefully evaluated. 
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For ENT-10.7/chloramphenicol, 27 laboratories 
reported MIC values but only 26 reported 
interpretation. This strain had an expected 
interpretation as ”R” based on an expected MIC 
value of 64 mg/L. Ten laboratories reported this 
strain as ”R” (MIC = 64 mg/L) whereas 16 
laboratories reported this strains as ”S” (MIC = 
32 mg/L). One laboratory obtained a MIC = 32 
mg/L but did not report interpretation. The result 
close to breakpoint caused 61% deviations, 
thus was omitted from the analysis in the report. 
For ST-10.4/ciprofloxacin, 25 laboratories 
reported results. This strain had an expected 
interpretation as ”R” based on an expected MIC 
value of 2 mg/L. Eleven  laboratories reported 
this strain as ”S” (with MIC = 1 mg/L). The result 
close to breakpoint caused 44% deviations, 
thus was omitted from the analysis in the report. 
For ST-10.8/ciprofloxacin, 25 laboratories 
reported results. This strain had an expected 
interpretation as ”S” based on an expected MIC 
= 1 mg/L. Ten laboratories reported this strain 
as ”R”. Eight laboratories reported MIC = 2 
mg/L, one laboratory reported MIC > 1 mg/L, 
and one laboratory reported MIC > 8 mg/L. 
Whereas this last measurement is likely to 
represent an AST performance problem, 36% 
deviations were due to “one-step dilution” 
issues in presence of an expected result closed 
to breakpoint, and thus this strain/antimicrobial 
combination was omitted from the analysis in 
the report. 
For EC-10.8/ertapenem, 30 and 29 participants 
uploaded MIC values and interpretation, 
respectively. This strain had an expected 
interpretation as ”R” based on an expected MIC 
value of 0.12 mg/L. Twelve laboratories 
reported this strain as ”R” based on: MIC = 0.12 
mg/L in ten laboratories; MIC = 0.25 mg/L in 
one laboratory; and MIC = 0.03 mg/L in one 
laboratory (of note, this last interpretation 
deviates from EUCAST ECOFF). Seventeen 
laboratories reported this strains as ”S” based 
on: MIC = 0.06 mg/L in 15 laboratories, MIC = 
0.03 mg/L in one laboratory and MIC ≤ 0.015 
mg/L in one laboratory. One additional 
laboratory obtained a MIC = 0.06 mg/L but did 
not report interpretation. Overall, 59% reported 
results deviated from expected ones, and 88% 
of these deviations were caused by the 
expected result close to breakpoint. Therefore, 
this strain/antimicrobial combination was 
omitted from the analysis in the report. 
Exclusion of these results is based on the fact 
that deviations caused by “one-fold dilution 
issues” cannot be considered representative of 
the ability of the laboratories to perform AST.  
3.2 Overall performance 
The percentage of results in agreement with 
those expected ranged from 95.2% (strain ST-
10.6) to 100% (strains ENT-10.1, ST-10.1 and 
EC-10.7) (Table 2). The E. coli trial yielded the 
highest percentage of correct results (99.2%), 
tightly followed both by the enterococci trial 
(98.7%) and by the staphylococci trial (98.4%). 
The percentage of deviations from the expected 
results appears to be very low and stable, with 
only minor fluctuations, for enterococci and 
Escherichia coli since 2013, and for 
staphylococci since 2014 (Figure 2). The results 
for the internal control strains appear to be 
stable for enterococci and E. coli since 2014, 
whereas notable improvements in the results of 
the internal control S. aureus strain were 
observed compared to previous years (Figure 
2). The list of deviations is reported in 
Appendices 8a, 8b and 8c.  
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3.2.1 Enterococci  
Twenty-eight laboratories (from 25 MS and 
three non-EU countries) approved results for 
the enterococci trial.  
At the EURL-AR workshop 2016, it was 
unanimously decided that reporting 
interpretation of quinupristin/dalfopristin MIC 
values for E. faecalis should not be considered 
a deviation although this species is intrinsically 
resistant to such antimicrobial. Thus, results are 
considered correct both when interpretation is 
not reported and when interpretation is R. An 
interpretation as S for the 
quinupristin/dalfopristin-E. faecalis combination 
is a deviation. No results deviating from those 
expected were observed for ENT-10.1. For the 
Table 2. Number of total and correct (%) antimicrobial susceptibility tests (AST) performed in the EURL-AR EQAS 2016  

















ENT10.1 310  310  100%  ST10.1 357  357  100%  EC10.1 651  645  99.1% 
ENT10.2 299  296  98.9%  ST10.2 357  353  98.9%  EC10.2 651  649  99.7% 
ENT10.3 322  321  99.7%  ST10.3 357  356  99.7%  EC10.3 649  640  98.6% 
ENT10.4 300  297  99.0%  ST10.4 330  326  98.7%  EC10.4 650  646  99.4% 
ENT10.5 322  315  97.8%  ST10.5 357  351  98.3%  EC10.5 651  648  99.5% 
ENT10.6 302  296  98.0%  ST10.6 355  338  95.2%  EC10.6 434  430  99.1% 
ENT10.7 265  261  98.4%  ST10.7 356  352  98.9%  EC10.7 434  434  100.0% 
ENT10.8 308  301  97.7%  ST10.8 330  320  97.0%  EC10.8 620  612  98.7% 
*ENT, enterococci; ST, staphylococci; EC, Escherichia coli. 
 
 
Figure 2. Overall deviations (%) from expected results by EQAS iteration. ENT, enterococci; ST, staphylococci; EC, 






















Enterococci Staphylococci Escherichia coli
ENT int ctrl ST int ctrl EC int ctrl
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remaining strains, deviations ranged from 0.3% 
for ENT-10.3 to 2.8% for ENT-10.8 (Figure 3). 
Although several cases of disagreement in 
interpretation (i.e. the participant uploaded a 
MIC value in agreement with the expected but 
interpreted it differently from what 
recommended in  the protocol) were observed, 
as well as “one-fold dilution issues” (especially 
for strain ENT-10.8), true performance 
problems appeared evident especially for ENT-
10.2, ENT-10.6 and ENT-10.7. 
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Deviations from expected results were obtained 
for all antimicrobials except daptomycin (Figure 
4). The antimicrobials that resulted in highest 
percentages of deviations were quinupristin-
dalfopristin (5.7%), ampicillin (3.7%), and 
gentamicin (2.2 %). Analysis of these deviations 
revealed that problems were not linked to poor 
test performance for ampicillin. For ampicillin 
most (7/8, 87%) deviations were due to 
expected MIC value close to breakpoint for 
resistance (“one-fold dilution issues”) for strains 
Figure 3. Deviations (%) from expected interpretation of AST result for each Enterococcus sp. strain, EURL-
AR EQAS 2016. 
Figure 4. Deviations (%) from expected interpretation of AST results for each antimicrobial. Enterococci 
component of the EURL-AR EQAS 2016. AMP, ampicillin; CHL, chloramphenicol; CIP, ciprofloxacin; DAP, 
daptomycin; ERY, erythromycin; GEN, gentamicin; LZD, linezolid; SYN, quinupristin/dalfopristin (synercid); 







































































































ENT-10.5 and ENT-10.8. Ampicillin deviations 
were obtained by eight laboratories. Regarding 
quinupristin-dalfopristin deviations, five 
deviations were obtained by three laboratories 
and all except one represented “one-fold 
dilution issues” or different interpretation of MIC 
values otherwise obtained as expected. 
Regarding gentamicin deviations, the five 
deviations observed were true wrong results 
obtained by two laboratories.  
An overview of obtained and expected results is 
reported in Appendix 7a. 
Enterococci species identification 
Participants were requested to identify the 
enterococci species as a mandatory 
component. The test strains were five E. 
faecalis (ENT-10.1, ENT-10.2, ENT-10.4, ENT-
10.6 and ENT-10.7) and three E. faecium (ENT-
10.3, ENT-10.5, ENT-10.8). Species 
identification results were uploaded by all 
participants with the exception of Lab #38 who 
did not report results for any of the strains and 
Lab #41 who did not report results for ENT-10.7 
and ENT-10.8. Two out of 214 (0.9%) results 
were in disagreement with those expected. This 
was caused by one participant (Lab #59) 
reporting a wrong identification of strains ENT-
10.7 and ENT-10.8. 
3.2.2 Staphylococci 
Twenty-seven laboratories (from 24 MS and 
three non-MS) uploaded results for the 
staphylococci trial. 
No results deviating from those expected were 
observed for ST-10.1. For the remaining 
strains, deviations ranged from 0.3% in ST-10.3 
to 4.8% in ST-10.6 (Figure 5). For each strain, 
at least half of the deviations obtained 
suggested AST performance issues. 
The antimicrobials that resulted in highest 
percentages of deviations were 
sulfamethoxazole-trimethoprim (21.2%), 
quinupristin-dalfopristin (4.4%) and tiamulin 
(3.3%) (Figure 6). For sulfamethoxazole/
trimethoprim, seven deviations in three strains 
were obtained by four laboratories out of 33 results 
reported in total (for all strains and by all 
laboratories). Of note, only those four 
laboratories submitted results for 
sulfamethoxazole/trimethoprim. Three 
deviations were ”one-fold dilution issues”. In three 
cases no MIC values were reported, but 
interpretation was uploaded and it was in 
disagreement with that expected. The 
remaining deviation might represent a MIC 
reading issue. For quinupristin/dalfopristin 
(synercid), eight deviations in four strains were 
obtained by six laboratories out of 183 results 
reported for all strains and from all laboratories. 
Three deviations (three strains/two laboratories) 
represented true incongruences from expected 
results whereas the remaining five deviations 
were ”one-fold dilution issues”. For tiamulin, six 
deviations in three strains were reported by five 
laboratories, with three deviations from three 
laboratories representing “one-fold dilution 
issues” and the remaining deviations 
suggesting performance issues. 
An overview of obtained and expected results is 
reported in Appendix 7b. 
Methicillin-resistant S. aureus 
Participants were requested to identify the 
presence/absence of methicillin resistance as a 
mandatory component. The test strains 
included five methicillin-resistant S. aureus 
(MRSA; ST-10.1, ST-10.2, ST-10.4, ST-10.5, 
ST-10.6) and three methicillin-susceptible S. 
aureus (MSSA;  ST-10.3,  ST-10.7,  ST-10.8). All 
participants submitted MRSA/MSSA results. Two 
out of 216 (0.9%) results were in 
disagreement with those expected. This was 
caused by one participant (Lab #40) reporting a 
wrong methicillin resistance phenotype for 
strains ST-10.6 and ST-10.8. 
13 
 3.2.3 Escherichia coli  
Thirty-one laboratories (from 28 MS and three 
non-MS) uploaded results for the E. coli trial. 
No results deviating from those expected were 
observed for EC-10.7. For the remaining 
strains, deviations from expected results ranged 
Figure 5. Deviations (%) from expected interpretation of AST results for each Staphylococcus aureus strain, 
EURL-AR EQAS 2016. 
Figure 6. Deviations (%) from expected interpretation of AST results for each antimicrobial. Staphylococcus 
aureus component of the EURL-AR EQAS 2016. CHL, chloramphenicol; CIP, ciprofloxacin; CLN, 
clindamycin; ERY, erythromycin; FOX, cefoxitin; GEN, gentamicin; LZD, linezolid; MUP, mupirocin; SYN, 
quinupristin/dalfopristin (synercid); SMX, sulfamethoxazole; SXT, sulfamethoxazole-trimethoprim; TET, 





































































































from 0.3 % for EC-10.2 to 1.4% for EC-10.3 
(Figure 7). For each strain, at least half of the 
deviations obtained represented “one-fold 
dilution issues” or different interpretation of MIC 
values, with the exception of deviations in EC-
10.6 and EC-10.8 which suggested 
performance problems. 
No deviations from expected results were 
obtained when testing susceptibility to 
ampicillin, imipenem, meropenem, gentamicin 
and nalidixic acid (Figure 8). The antimicrobials 
that resulted in highest percentages of 
deviations were cefepime (4.3 %), 
sulfamethoxazole (2.4 %), and colistin and 
trimethoprim (both with 1.6 % deviations) 
(Figure 8). Eight cefepime deviations were 
obtained by four laboratories. Analysis of 
cefepime deviations revealed that most of them 
(5/8, 62.5%) were due either to interpretation of 
MIC values different from the recommend 
protocol or “one-fold dilution issues”, whereas 
the remaining three were likely to represent 
performance issue. Four colistin deviations 
were obtained by three laboratories. Three of 
them (75%) represented “one-fold dilution 
issues” and only one suggested performance 
problems. For sulfamethoxazole, six deviations 
in two strains were obtained by four 
laboratories, whereas for trimethoprim, four 
deviations in two strains were obtained by four 
laboratories. For these antimicrobials, results 
appeared to be true deviations possibly linked 
to the fact that those MICs might be difficult to 
define. 
An overview of obtained and expected results is 
reported in Appendix 7c.  
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Beta-lactamase-producing E. coli 
Participants were requested to detect the 
production of beta-lactamases and classify the 
beta-lactam resistance phenotype into 
Extended-Spectrum Beta-Lactamase


























































































































Figure 8. Deviations (%) from expected interpretation of AST results for each antimicrobial. Escherichia 
coli component of the EURL-AR EQAS 2016. AMP, ampicillin; AZI, azithromycin; FEP, cefepime; FOT, 
cefotaxime; TAZ, ceftazidime; CHL, chloramphenicol; CIP, ciprofloxacin; COL, colistin; ETP, ertapenem; 
GEN, gentamicin; IMI, imipenem; MERO, meropenem; NAL, nalidixic acid; SMX, sulfamethoxazole; TET, 
tetracycline; TGC tigecycline; TMP trimethoprim
Figure 7. Deviations (%) from expected interpretation of AST results for each Escherichia coli strain, 
EURL-AR EQAS 2016. 
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Guidelines for interpretation of the beta-lactam 
resistance phenotype were specified in the 
protocol (Appendix 4b) and were in agreement 
with the latest recommendations by EFSA. 
In this EQAS, EC-10.2, EC-10.3 and EC-10.4 
were ESBL producers; EC-10.1 and EC-10.8 
were AmpC beta-lactamase producers and EC-
10.5 was a carbapenemase producer. The 
remaining strains (EC-10.6 and EC-10.7) did 
not produce any beta-lactamase. 
All 31 participants uploaded results for this part 
of the E. coli trial. No wrong detection of 
ESBL/AmpC/carbapenemase-producing E. coli 
was observed, though deviations from correct 
classification of the phenotype of some of the 
strains were reported for seven (23%) 
laboratories, probably due to the fact that the 
criteria for categorisation of beta-lactam 
resistance were not clear to some participants 
(Figure 9). Six laboratories classified EC-10.1 
as “Presumptive ESBL+AmpC” instead of 
“Presumptive AmpC”. This strain produced 
CMY-2 and TEM-1 beta-lactamase. 
The same six laboratories had problems also in 
interpretation of beta-lactam resistance of EC-
10.8: five and one laboratories reported this 
strain as “Presumptive ESBL+AmpC” and 
“Other phenotype”, respectively, instead of 
“Presumptive AmpC”. This strain produced 
CMY-2 beta-lactamase. 
One laboratory classified EC-10.4 as 
“Presumptive ESBL+AmpC” instead of 
“Presumptive ESBL” probably linked to 
erroneous detection/reporting of cefoxitin 
resistance. This strain produced SHV-12 beta-
lactamase. 
EC-10.2, EC-10.3and EC-10.5 producing CTX-
M-1, SHV-12 and VIM-1 beta-lactamases were 
correctly classified by all participants. 
Figure 9. Deviations (%) in classification of beta-lactam resistance phenotype for each 
























































3.3 Performance by individual 
laboratories 
The figures 10, 11 and 12 illustrate the 
percentage of deviations that each laboratory 
obtained in the three MIC 
determination/interpretation trials. 
3.3.1 Enterococci 
Seventeen laboratories (61%) reported results 
in full agreement with those expected (Figure 
10). 
Nine laboratories had between 1% and 4.2% 
deviations (Figure 10). Of these, seven 
laboratories obtained deviations due to “one-
fold dilution issues” or to interpretation of the 
MIC values (obtained as expected) different 
from the protocol. This suggests no problems in 
AST performance in these laboratories, though 
reasons for interpreting MIC values differently 
from what indicated in the protocol are unclear 
and will be followed-up. The remaining two 
laboratories obtained deviations partly due to 
“one-fold dilution issues” and partly due to true 
deviations such as vancomycin and teicoplanin 
MIC different from the expected in one strain 
(Lab #42), and ciprofloxacin MIC different from 
the expected in one strain (Lab #39), which 
suggest some performance issues. 
Two laboratories had percentages of deviations 
(11% and 7%) above the threshold for 
acceptable laboratory performance (5%) 
(Figure 10). Lab #40 had nine deviations in five 
strains. All but one (which was a “one-fold 
dilution issue”) likely represent 
performance/reading problems. 
Lab #45 had six deviations in four strains. Half 
of them were ”one-fold dilution issues”, and two 
might indicate problems in gentamicin 
susceptibility testing. Follow-up with these 
laboratories is ongoing. 
Deviations from expected results obtained by 
each participant in the enterococci trial are 
reported in Appendix 8a. 
3.3.2 Staphylococci 
Fifteen laboratories (55%) reported results in 
full agreement with those expected (Figure 11). 
Nine laboratories obtained between 0.9% and 
3.4% deviations (Figure 11). All deviations 
obtained by these laboratories represented 
either “one-fold dilution issues” or problems in 
defining the MICs of sulfamethoxazole or 
sulfamethoxazole/trimethoprim. Thus, although 
reassuring of the overall good AST performance 
of these laboratories, these results reveal that 
reading MICs of sulfamethoxazole or 
sulfamethoxazole/trimethoprim for
staphylococci present challenges that need to 
be addressed. 
Three laboratories had percentages of 
deviations (12.7%, and 7.2% for two 
laboratories) above the threshold for acceptable 
laboratory performance (5%) (Figure 11). 
Lab #40 had 14 deviations in three strains and 
identified the issue just after the EQAS deadline 
by realising that most (93%) of the deviations 
were due to a switch of two strains. This 
represents a serious strain management issue 
but not a MIC determination problem. 
Lab #17 had eight deviations in two strains. 
Also in this case the participant followed-up 
soon after the EQAS deadline and sent the 
strains back to the EURL-AR for confirmatory 
testing. AST by the EURL-AR confirmed the 
participant’s results, thus also in this case there 
seemed to be no problem in performance of 
MIC determination.  Whole genome sequencing 
is ongoing to determine if there was loss of 
resistance genes at some point during 
shipment/storage. Notably, no other participant 
experienced this issue.  
Lab #45 had eight deviations in four strains. 
Two deviations were ”one-fold dilution issues”, 
whereas the remaining might suggest problems 
in AST of staphylococci. Lab #45 obtained > 5% 
deviations also in the enterococci trial, which 
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might indicate a general problem when testing 
Gram-positive bacteria. 
Deviations from expected results obtained by 
each participant in the staphylococci trial are 
reported in Appendix 8b. 
3.3.3 Escherichia coli  
Fourteen laboratories (45%) reported results in 
full agreement with those expected (Figure 12). 
Ten laboratories (32%) had 0.6% deviations 
representing one deviation per laboratory 
(Figure 12). Five of these deviations were “one-
fold dilution issues” or interpretation of the MIC 
values (obtained as expected) different from the 
protocol. The remaining deviations indicate 
issues in testing/reporting susceptibility to 
cefoxitin, tetracycline, tigecycline and 
trimethoprim in different strains. 
Three laboratories (10%) obtained 1.3% 
deviations representing two deviations per 
laboratory (Figure 12). Three of these 
deviations were “one-fold dilution issues” or 
interpretation of the MIC values (obtained as 
expected) different from the protocol. The 
remaining deviations indicate issues in 
testing/reporting susceptibility to 
sulfamethoxazole and tetracycline in different 
strains. 
One laboratory (3%) obtained 4 deviations 
(Figure 12) of which one represented a possible 
colistin susceptibility testing issue, whereas the 
remaining were “one-fold dilution issues”. 
One laboratory (3%) obtained 5 deviations 
(Figure 12) which were all indicative of issues in 
performance of azithromycin, cefepime and 
sulfamethoxazole susceptibility testing. 
Finally, one laboratory (3%) obtained eight 
deviations (Figure 12) thus being on the 
threshold for acceptable laboratory 
performance. Three deviations were linked to 
interpretation of the cefepime MIC values 
(obtained as expected) different from the 
protocol, whereas the remaining deviations 
suggested issues in performance of 
sulfamethoxazole and trimethoprim 
susceptibility testing. 
3.4 Performance in AST of the 
quality control strains 
Antimicrobial susceptibility test results for the 
quality control strains were evaluated based on 
the CLSI quality control ranges (Appendix 5). 
3.4.1 Enterococcus faecalis ATCC 29212 
Of the 28 participants in the enterococci trial, 27 
performed AST of E. faecalis ATCC 29212 by 
MIC determination reporting a total of 288 test 
results, of which four (1.4%) were outside the 
acceptable range (Table 3). These deviations 
were obtained by two laboratories: one had 
three deviations that might represent 
performance issues whereas the other most 
likely performed a typo in entering the results 
on the database. 
3.4.2 Staphylococcus aureus ATCC 29213 
Of the 27 participants in the staphylococci trial, 
24 performed AST of S. aureus ATCC 29213 by 
MIC determination reporting a total of 254 test 
results, which were all (100%) within the 
acceptable range (Table 4). 
3.4.3 Escherichia coli ATCC 25922 
Of the 31 participants in the E. coli trial, 30 
tested E. coli ATCC 25922 by MIC 
determination on panel 1 reporting a total of 
389 test results, of which four (1%) were 
outside the acceptable range (Table 5). 
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Figure 10. Deviations (%) by participating laboratory in the enterococci trial, EURL-AR EQAS 2016. The dashed line 
indicates the threshold (5%) for acceptable laboratory performance. 
Figure 11. Deviations (%) by participating laboratory in the staphylococci trial, EURL-AR EQAS 2016. The dashed line 
indicates the threshold (5%) for acceptable laboratory performance. 
Figure 12. Deviations (%) by participating laboratory in the Escherichia coli trial, EURL-AR EQAS 2016. The dashed line 





































































These deviations were obtained by four 
laboratories measuring MIC of trimethoprim one 
step below the acceptable range and one 
laboratory measuring MIC of sulfamethoxazole 
one step above the acceptable range (Table 5). 
E. coli ATCC 25922 was tested for susceptibility
to antimicrobials in panel 2 by 28 laboratories 
reporting 193 test results all (100%) within the 
acceptable range (Table 5). 
Further details on test results of quality control 
strains are reported in Appendix 6. 
Table 3. Antimicrobial susceptibility testing of 












Ampicillin 0/26 (0%) − − 
Chloramphenicol 0/27 (0%) − − 
Ciprofloxacin 1/26 (3.8%) 1 step 
Daptomycin 1/25 (4) 2 steps 
Erythromycin 0/27 (0%) − − 
Gentamicin 0/26 (0%) − − 
Linezolid 0/27 (0%) − − 
Quinu/dalfopristin  0/0 − − 
Teicoplanin 0/24 (0%) − − 
Tetracycline 0/27 (0%) − − 
Tigecycline 2/26 (7.7%) − 1 step (1) typo (1) 
Vancomycin 0/27 (0%) − − 
Table 4. Antimicrobial susceptibility testing of 












Cefoxitin 0/23 (0%) − − 
Chloramphenicol 0/23 (0%) − − 
Ciprofloxacin 0/23 (0%) − − 
Clindamycin 0/23 (0%) − − 
Erythromycin 0/24 (0%) − − 
Gentamicin 0/23 (0%) − − 
Linezolid 0/22 (0%) − − 
Mupirocin no range − − 
Quinu/dalfopristin  0/0 − − 
Sulfamethoxazole 0/22 (0%) − − 
Sulfa/Trimethoprim 0/2 (0%) − − 
Tetracycline 0/24 (0%) − − 
Tiamulin no range − − 
Trimethoprim 0/23 (0%) − − 
Vancomycin 0/22 (0%) − − 
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4. Conclusions
This report presented the result of the EURL-
AR EQAS 2016 for E. coli, enterococci and 
staphylococci. This proficiency test evaluated 
the performance in i) MIC determination and 
interpretation, ii) enterococci species 
identification and iii) detection of relevant 
phenotypes such as methicillin resistance in S. 
aureus and beta-lactam resistance mediated by 
ESBL/AmpC/carbapenemase in E. coli. 
Participants invited to this EQAS were NRL-AR 
from each MS and additional laboratories 
affiliated to the EURL-AR network including 
laboratories from non-MS and laboratories 
other than NRL-AR in MS. 
Results from NRL-AR and from one laboratory 
per non-MS were analysed in this report, 
leading to a total of 28 (25 MS and 3 non-MS), 
27 (24 MS and 3 non-MS) and 31 (28 MS and 3 
non-MS) sets of results analysed for 
enterococci, staphylococci and E. coli, 
respectively. 
In the MIC determination and interpretation 
component, two, three and none laboratories 
obtained more than 5% deviations in the 
enterococci, staphylococci and E. coli trial, 
respectively. Communication between the 
EURL-AR and these underperforming 
laboratories is ongoing to assess the causes of 
the high percentages of deviations and to 
identify possible troubleshooting procedures. 
One case was peculiar, since the EURL-AR 
confirmed the participant’s results – in 
disagreement with those expected – upon re-
testing of the EQAS strains sent back from the 
participant. In this case, the high percentage of 
deviations is not linked to AST performance but 
likely to loss of resistance genes. WGS is 
ongoing to try to solve this issue. The fact that 
no other participant experienced a similar 
problem adds to the odd case. 
For all participants obtaining deviations, 
although a notable proportion of deviations was 
due to “one-fold dilutions issues” (which are 
unavoidable with the used methods and do not 
indicate AST performance problems), 
improvements can still be pursued. Deviations 
due to different interpretation of the same MIC 
values were detected, which could easily be 
avoided. Issues related to strain management 
as well as MIC reading occurred too, and 
correction of these errors require internal 
troubleshooting that might differ in the different 
NRLs, and the EURL-AR is available for 
assistance if requested. 
Overall, performance in the MIC determinations 
and interpretation component was consistent 
with that observed in recent EQAS iterations. 
Enterococci species identification was 
performed correctly by all laboratories except 
Table 5. Antimicrobial susceptibility testing of 











Ampicillin 0/30 (0%) − − 
Azithromycin no range − − 
Cefotaxime 0/29 (0%) − − 
Ceftazidime 0/30 (0%) − − 
Chloramphenicol 0/30 (0%) − − 
Ciprofloxacin 0/30 (0%) − − 
Colistin 0/30 (0%) − − 
Gentamicin 0/30 (0%) − − 
Meropenem 0/30 (0%) − − 
Nalidixic acid 0/30 (0%) − − 
Sulfamethoxazole 1/30 (3.3%) − 1 step 
Tetracycline 0/30 (0%) − − 
Tigecycline 0/30 (0%) − − 
Trimethoprim 3/30 (10%) 1 step − 
Cefepime 0/28 (0%) − − 
Cefotaxime 0/28 (0%) − − 
Cefotaxime/clavulanic 
acid no range − − 
Cefoxitin 0/28 (0%) − − 
Ceftazidime 0/28 (0%) − − 
Ceftazidime/clavulanic 
acid no range − − 
Ertapenem 0/28 (0%) − − 
Imipenem 0/28 (0%) − − 
Meropenem 0/28 (0%) − − 
Temocillin no range − − 
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one, and in addition one laboratory did not 
perform this component. Though the results are 
overall excellent, assistance to those two 
laboratories will be offered. 
Detection of methicillin resistance in S. aureus 
was correctly performed by all laboratories 
except one. The reason for the deviation was 
detected by the participant immediately after 
the EQAS deadline, and such self-evaluation 
represents a first important step to avoid that 
the same problem recurs in the future. 
Detection of ESBL/AmpC/carbapenemase 
production in E. coli was correctly performed by 
all laboratories, though interpretation of the 
phenotype was challenging for some of them. 
This might be linked to the newly adopted 
criteria for classification of beta-lactam 
resistance phenotypes in this EQAS iteration. 
Communication with those participants was 
performed to clarify the classification scheme. 
Colistin resistance in E. coli, a phenotype that 
acquired notable importance recently, was 
overall correctly detected, though some 
challenges when resistance mechanisms 
mediated a MIC just above the breakpoint for 
resistance were observed. Thus, one strain was 
incorrectly categorised as susceptible by two 
(out of 31; 6%) participants and one participant 
incorrectly classified as susceptible both 
colistin-resistant strains included in this EQAS. 
Colistin susceptibility testing is undoubtedly 
challenging, and all necessary QC procedures 
should be implemented to ensure valid results. 
Such QC procedures are periodically updated 
by EUCAST and publicly available 
(www.eucast.org). Laboratories in the network 
are welcome to ask the EURL-AR for 
assistance on this issue. 
Finally, the EURL-AR welcomes suggestions for 
improvement of future EQAS trials and invites 
the network to contribute with ideas for 
newsletters and for training needs, with the 
overall goal to continuously improve the 
knowledge and skills of the laboratories 
involved in the AMR monitoring. 
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EU Reference Laboratory, Antimicrobial Resistance, Søltofts Plads, Building 221, DK-2800 Kgs. Lyngby, Denmark.  
Phone: + 45 3588 6601, Fax: + 45 3588 6341, e-mail: suska@food.dtu.dk
EURL-AR EQAS pre-notification 
EQAS 2016 FOR E. COLI, STAPHYLOCOCCI AND ENTEROCOCCI 
The EURL-AR announces the launch of another EQAS, thus providing the opportunity for proficiency 
testing which is considered an essential tool for the generation of reliable laboratory results of consistently 
good quality. 
This EQAS consists of antimicrobial susceptibility testing of eight E. coli isolates, eight staphylococci and 
eight enterococci isolates. Additionally, quality control (QC) strains E. coli ATCC 25922 (CCM 3954), E. 
faecalis ATCC 29212 (CCM 4224) and S. aureus ATCC 29213 (CCM 4223) (for MIC) will be distributed to 
new participants. 
This EQAS is specifically for NRL’s on antimicrobial resistance. Laboratories designated to be NRL-AR do 
not need to sign-up to participate but are automatically regarded as participants. You may contact the EQAS-
Coordinator if you wish to inform of changes in relation to your level of participation in previous years. The 
EURL-AR will be able to cover the expenses for one parcel, only, per EU Member State. Therefore, 
countries with more than one laboratory registered on the EURL-AR contact-list will be contacted directly to 
confirm which laboratory will be included for participation free of charge.  
The invitation to participate in the proficiency test is extended to additional participants from official NRLs 
and participants from laboratories which are involved in the network but are not designated NRLs (cost for 
participation will be 100 euro). 
TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
The content of the parcel is “UN3373, Biological Substance Category B. Eight E. coli, eight staphylococci, 
eight enterococci and for new participants also the QC strains mentioned above. Please provide the EQAS 
coordinator with documents or other information that can simplify customs procedures (e.g. specific text that 
should be written on the proforma invoice). To avoid delays, we kindly ask you to send this information 
already at this stage.  
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol: The isolates will be shipped in June 2016. The protocol for this 
proficiency test will be available for download from the website (www.eurl-ar.eu).  
Submission of results: Results must be submitted to the National Food Institute no later than September, 
2nd, 2016, via the password-protected website.  
Upon reaching the deadline, each participating laboratory is kindly asked to enter the password-protected 
website once again to download an automatically generated evaluation report. 
EQAS report: A report summarising and comparing results from all participants will be issued. In the report, 
laboratories will be presented coded, which ensures full anonymity. The EURL-AR and the EU Commission, 
only, will have access to un-coded results. The report will be publicly available. 
Next EQAS: The next EURL-AR EQAS that we will have is on antimicrobial susceptibility testing of 
Salmonella and Campylobacter and a new EQAS on isolation of ESBL and ampC –producing E.coli from 
samples which are both expected to be carried out in October, 2016. 
Please contact me if you have comments or questions regarding the EQAS. 
Sincerely, 
Susanne Karlsmose Pedersen, 
EURL-AR 
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Participants to the EURL-AR EQAS 2016
Institute  Country E. coli Ent Staph
Austrian Agency for Health and Food Safety Austria x x x
Institute of Public Health Belgium x no x
Nacional Diagnostic and Research Veterinary Institute Bulgaria x x x
Croatian Veterinary Institut Croatia x x x
Veterinary Services Cyprus x no no
State Veterinary Institute Praha Czech Republic x x x
Danish Veterinary and Food Administration Denmark x x no
Estonian Veterinary and Food Laboratory Estonia x x x
Finnish Food Safety Authority EVIRA Finland x x x
Agence nationale de sécurité sanitaire ANSES - Fougères France x x no
Federal Institute for Risk Assessment Germany x x x
Veterinary Laboratory of Chalkis Greece x no no
Central Agricultural Office Veterinary Diagnostic Directorate Hungary x x x
University of Iceland Iceland x x x
Central Veterinary Research Laboratory Ireland x x x
Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana Italy x x x
Institute of Food Safety, Animal Health and Enviroment "BIOR" Latvia x x x
National Food and Veterinary Risk Assessment Institute Lithuania x x x
Laboratoire national de Santé Luxembourg x x x
Veterinary Services Malta x no no
Public Health Laboratory Malta x x x
Central Veterinary Institute of Wageningen UR Netherlands x x x
Food and Consumer Product Safety Authority (VWA) Netherlands x x x
Veterinærinstituttet Norway x x x
National Veterinary Research Institute Poland x x x
Laboratorio National de Investigacáo Veterinaria Portugal x x x
Institute for Diagnosis and Animal Health Romania x x x
Institute for Hygiene and Veterinary Public Health Romania x x x
State Veterinary and Food Institute  (SVFI) Slovakia x x x
National Veterinary Institute Slovenia x x x
Laboratorio Central de Sanidad, Animal de Algete Spain x x no
Laboratorio Central de Sanidad, Animal de Santa Fe Spain no no x
VISAVET Health Surveillance Center, Complutense University Spain x x x
Agencia Espanola de Seguridad Alimentria y Nutricion Spain x x no
National Veterinary Institute, SVA Sweden x x x
Vetsuisse faculty Bern, Institute of veterinary bacteriology Switzerland x x x
The Veterinary Laboratory Agency United Kingdom x x x
Color code
NRLs
non- NRL enrolled for  EQAS or extra NRL enrolled
not EU-member state 
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Expected MIC values
Strain ID Species Antimicrobial
DAP TIG TEI AMP CHL CIP ERY GEN LZD Q‐D TET VAN
EURL ENT 10.1 Enterococcus faecalis 2.0 0.25 <=0.5 1.0 8.0 1.0 >128.0 >1024.0 2.0 16.0 64.0 2.0
EURL ENT 10.2 Enterococcus faecalis 4.0 0.25 <=0.5 1.0 8.0 1.0 <=1.0 <=8.0 2.0 16.0 <=1.0 4.0
EURL ENT 10.3 Enterococcus faecium 1.0 0.06 >64.0 4.0 16.0 1.0 >128.0 <=8.0 2.0 8.0 64.0 >128
EURL ENT 10.4 Enterococcus faecalis 1.0 0.25 <=0.5 1.0 128.0 1.0 >128.0 256 2.0 32 128.0 <=1.0
EURL ENT 10.5 Enterococcus faecium 1.0 0.12 64.0 4.0 8.0 0.5 2.0 <=8.0 2.0 4.0 64.0 >128.0
EURL ENT 10.6 Enterococcus faecalis 2 0.25 <=0.5 1.0 128.0 1.0 >128.0 >1024.0 2.0 32.0 128.0 2.0
EURL ENT 10.7 Enterococcus faecalis 2 0.12 <=0.5 1 64 2 >128 <=8.0 8 16 128 2
EURL ENT 10.8 Enterococcus faecium 1.0 0.12 <=0.5 4.0 8.0 2.0 >128.0 <=8.0 2.0 4.0 64.0 <=1.0
Expected interpretation
Strain ID Species Antimicrobial
DAP TIG TEI AMP CHL CIP ERY GEN LZD Q‐D TET VAN
EURL ENT 10.1 Enterococcus faecalis S S S S S S R R S NA R S
EURL ENT 10.2 Enterococcus faecalis S S S S S S S S S NA S S
EURL ENT 10.3 Enterococcus faecium S S R S S S R S S R R R
EURL ENT 10.4 Enterococcus faecalis S S S S R S R R S NA R S
EURL ENT 10.5 Enterococcus faecium S S R S S S S S S S R R
EURL ENT 10.6 Enterococcus faecalis S S S S R S R R S NA R S
EURL ENT 10.7 Enterococcus faecalis S S S S R S R S R NA R S
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Expected MIC values
Strain ID Species
VAN Q‐D LZD MUP CLN CHL CIP ERY FOX** GEN SMX TET TIA TMP SXT
EURL ST 10.1 Staphylococcus aureus <=1.0 8.0 2.0 0.064 12 8.0 0.25 >16.0 16.0 <=0.25 64.0 >32.0 >32.0 >32.0 0.5
EURL ST 10.2 Staphylococcus aureus <=1.0 8.0 2.0 0.064 16 8.0 0.25 >16.0 16.0 0.5 <=32.0 >32.0 >32.0 >32.0 0.5
EURL ST 10.3 Staphylococcus aureus <=1.0 <=0.5 2.0 0.064 0.125 8 0.25 0.5 4 <=0.25 <=32.0 <=0.5 1 1 <=0.25
EURL ST 10.4 Staphylococcus aureus <=1.0 <=0.5 2.0 0.094 0.125 8.0 2.0 <=0.25 8.0 >16.0 >512.0 32.0 0.5 1.0 <=0.25
EURL ST 10.5 Staphylococcus aureus <=1.0 1.0 2.0 0.064 >256 8.0 0.5 >16.0 32.0 0.5 128.0 >32.0 0.5 >32.0 2.0
EURL ST 10.6 Staphylococcus aureus <=1.0 2.0 2.0 0.064 >256 8.0 >8.0 >16.0 8.0 16.0 <=32.0 >32.0 4.0 >32.0 1.0
EURL ST 10.7 Staphylococcus aureus <=1.0 <=0.5 2.0 0.094 0.125 8.0 0.25 0.5 4.0 <=0.25 64.0 <=0.5 0.5 2.0 <=0.25
EURL ST 10.8 Staphylococcus aureus <=1.0 <=0.5 2.0 0.064 0.094 8.0 1 0.5 4.0 0.5 64.0 >32.0 1.0 >32 1.0
Expected interpretation
Strain ID Species MRSA* Gene detected
VAN Q‐D LZD MUP CLN CHL CIP ERY FOX GEN SMX TET TIA TMP SXT
EURL ST 10.1 Staphylococcus aureus S R S S R S S R R S S R R R S positive mecA
EURL ST 10.2 Staphylococcus aureus S R S S R S S R R S S R R R S positive mecA
EURL ST 10.3 Staphylococcus aureus S S S S S S S S S S S S S S S negative NA
EURL ST 10.4 Staphylococcus aureus S S S S S S R S R R R R S S S positive mecA
EURL ST 10.5 Staphylococcus aureus S S S S R S S R R S S R S R R positive mecA
EURL ST 10.6 Staphylococcus aureus S R S S R S R R R R S R R R R positive mecA
EURL ST 10.7 Staphylococcus aureus S S S S S S S S S S S S S S S negative NA
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Expected MIC values
Strain ID Species
AMP MER COL CHL CIP TAZ FOT GEN NAL SMX TET TMP AZI TIG
EURL EC 10.1 Escherichia coli >64.0 <=0.03 8.0 <=8.0 >8.0 >8.0 >4.0 1.0 >128.0 >1024.0 >64.0 >32.0 8.0 0.5
EURL EC 10.2 Escherichia coli >64.0 <=0.03 <=1.0 <=8.0 <=0.015 4.0 >4.0 <=0.5 <=4.0 <=8.0 <=2.0 <=0.25 8.0 <=0.25
EURL EC 10.3 Escherichia coli >64 <=0.03 4.0 32.0 <=0.015 >8.0 4.0 1.0 <=4.0 >1024.0 64.0 <=0.25 4.0 0.5
EURL EC 10.4 Escherichia coli >64.0 <=0.03 <=1.0 32.0 <=0.015 8.0 2.0 1.0 <=4.0 >1024.0 64.0 <=0.25 4.0 0.5
EURL EC 10.5 Escherichia coli >64.0 4.0 <=1.0 <=8.0 0.03 >8.0 >4.0 2.0 <=4.0 16.0 <=2.0 <=0.25 4.0 <=0.25
EURL EC 10.6 Escherichia coli >64.0 <=0.03 <=1.0 <=8.0 0.25 <=0.5 <=0.25 1.0 <=4.0 >1024.0 64.0 >32.0 4.0 0.5
EURL EC 10.7 Escherichia coli 2.0 <=0.03 <=1.0 <=8.0 <=0.015 <=0.5 <=0.25 <=0.5 <=4.0 16.0 <=2.0 <=0.25 4.0 <=0.25
EURL EC 10.8 Escherichia coli >64.0 0.06 <=1.0 <=8.0 0.03 >8.0 >4.0 1.0 <=4.0 32 4.0 <=0.25 4.0 <=0.25
Expected interpretation
Strain ID Species
AMP MER COL CHL CIP TAZ FOT GEN NAL SMX TET TMP AZI TIG
EURL EC 10.1 Escherichia coli R S R S R R R S R R R R S S
EURL EC 10.2 Escherichia coli R S S S S R R S S S S S S S
EURL EC 10.3 Escherichia coli R S R R S R R S S R R S S S
EURL EC 10.4 Escherichia coli R S S R S R R S S R R S S S
EURL EC 10.5 Escherichia coli R R S S S R R S S S S S S S
EURL EC 10.6 Escherichia coli R S S S R S S S S R R R S S
EURL EC 10.7 Escherichia coli S S S S S S S S S S S S S S
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Expected MIC values
Strain ID Species
FOX TAZ TAZ+CL FOT FOT+CL FEP MER IMI ETP TRM
EURL EC 10.1 Escherichia coli 64 16 8/4 8 8/4 0.25 <=0.03 0.25 0.06 8
EURL EC 10.2 Escherichia coli 4 2 <=0.12/4 64 <=0.06/4 16 <=0.03 <=0.12 <=0.015 4
EURL EC 10.3 Escherichia coli 4 8 <=0.12/4 2 <=0.06/4 0.25 <=0.03 0.25 <=0.015 4
EURL EC 10.4 Escherichia coli 2 8 <=0.12/4 2 <=0.06/4 0.25 <=0.03 <=0.12 <=0.015 4
EURL EC 10.5 Escherichia coli 64 >128 128/4 >64 >64/4 32 4 4 0.5 64
EURL EC 10.6 Escherichia coli NR NR NR NR NR NR NR NR NR NR
EURL EC 10.7 Escherichia coli NR NR NR NR NR NR NR NR NR NR
EURL EC 10.8 Escherichia coli 64 8 8/4 16 8/4 0.25 <=0.03 0.25 0.12 8
Expected interpretation
Strain ID Species
FOX TAZ TAZ+CL* FOT FOT+CL* FEP MER IMI ETP TRM** ESBL AmpC ESBL+AmpC Carbapenemase Other None
EURL EC 10.1 Escherichia coli R R no synergy R no synergy R S S S NA no yes no no no no
EURL EC 10.2 Escherichia coli S R synergy R synergy R S S S NA yes no no no no no
EURL EC 10.3 Escherichia coli S R synergy R synergy R S S S NA yes no no no no no
EURL EC 10.4 Escherichia coli S R synergy R synergy R S S S NA yes no no no no no
EURL EC 10.5 Escherichia coli R R no synergy R no synergy R R R R NA no no no yes no no
EURL EC 10.6 Escherichia coli NR NR NR NR NR NR NR NR NR NR no no no no no yes
EURL EC 10.7 Escherichia coli NR NR NR NR NR NR NR NR NR NR no no no no no yes
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EURL-AR External Quality Assurance System (EQAS) 2016: 










Please find enclosed the bacterial strains for the EURL-AR EQAS 2016. Upon arrival to your 
laboratory, the strains should be stored in a dark place at 4C for stabs, and in a dark and cool 
place for freeze-dried strains.  
 
On the EURL-AR-website (www.eurl-ar.eu) the following documents relevant for the EURL-
AR EQAS are available: 
- Protocol for E. coli, staphylococci and enterococci including test forms  
- Instructions for Opening and Reviving Lyophilised Cultures 
- Subculture and Maintenance of Quality Control Strains  
 
We ask you to examine the eight E. coli, enterococci and S. aureus strains that we send to you 
by performing antimicrobial susceptibility testing. In the protocol you can find detailed de-
scription of the procedures to follow. Additionally, you can find a description of the proce-
dure to enter your results into the interactive web database. For accessing the database, you 
need this username and password: 
 
Your username: «Username» 
 
Your password: «Password» 
 
Please keep this document 
  Your username and password will not appear in other documents 
 
Results should be entered in the database no later than 2nd September 2016. Please 
acknowledge receipt of this parcel immediately upon arrival (to vabo@food.dtu.dk) and do not 
hesitate to contact me for further information. 
Yours sincerely, 
Valeria Bortolaia 
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For antimicrobial susceptibility testing of Escherichia coli, enterococci and staphylococci 
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3  OUTLINE OF THE EC/ENT/STAPH EQAS 2016 ............................................................ 2 
Shipping, receipt and storage of strains ............................................................................. 2 
Suggested procedure for reconstitution of the lyophilised reference strains .................. 2 
Antimicrobial susceptibility testing .................................................................................... 3 
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5  HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE ............................ 7 
5.1  AST of E. coli, enterococci and staphylococci ........................................................ 8 
APPENDIX ......................................................................................................................................... 9 
 
1 INTRODUCTION 
The organisation and implementation of an External Quality Assurance System (EQAS) on 
antimicrobial susceptibility testing (AST) of E. coli, enterococci and staphylococci is among the 
tasks of the EU Reference Laboratory for Antimicrobial Resistance (EURL-AR). The EC/Ent/Staph 
EQAS 2016 will include AST of eight Escherichia coli, eight enterococci and eight staphylococci 
strains and AST of reference strains E. coli ATCC 25922 (CCM 3954), E. faecalis ATCC 29212 
(CCM 4224), and S. aureus ATCC 29213 (CCM 4223).  
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The above-mentioned reference strains are included in the parcel only for new participants of the 
EQAS who did not receive them previously. The reference strains are original CERTIFIED cultures 
provided free of charge, and should be used for future internal quality control for antimicrobial 
susceptibility testing in your laboratory. The reference strains will not be included in the years to 
come. Therefore, please take proper care of these strains. Handle and maintain them as suggested in 
the manual ‘Subculture and Maintenance of QC Strains’ available on the EURL-AR website (see 
www.eurl-ar.eu).  
Various aspects of the proficiency test scheme may from time to time be subcontracted. When 
subcontracting occurs it is placed with a competent subcontractor and the National Food Institute is 
responsible to the scheme participants for the subcontractor’s work.  
2 OBJECTIVES 
This EQAS aims to support laboratories to assess and, if necessary, to improve the quality of results 
obtained by AST of pathogens of food- and animal-origin, with special regard to E. coli, 
enterococci and staphylococci. Further objectives are to evaluate and improve the comparability of 
surveillance data on antimicrobial susceptibility of E. coli, enterococci and staphylococci reported 
to EFSA by different laboratories. 
3 OUTLINE OF THE EC/ENT/STAPH EQAS 2016 
Shipping, receipt and storage of strains 
In June 2016, the National Reference Laboratories for Antimicrobial Resistance (NRL-AR) will 
receive a parcel containing eight E. coli, eight enterococci and eight staphylococci strains from the 
DTU National Food Institute. This parcel will also contain reference strains, but only for 
participants who did not receive them previously. 
All strains belong to UN3373, Biological substance, category B. Extended-spectrum beta-lactamase 
(ESBL)-producing strains as well as carbapenemase-producing strains and methicillin-resistant 
Staphylococcus aureus (MRSA) will be included in the selected material.  
The reference strains are shipped lyophilised, while the test strains are stab cultures. On arrival, the 
stab cultures must be subcultured, and all cultures should be adequately stored until testing. A 
suggested procedure for reconstitution of the lyophilised reference strains is presented below.  
Suggested procedure for reconstitution of the lyophilised reference strains  
Please refer to the document ‘Instructions for opening and reviving lyophilised cultures’ reported on 
the EURL-AR-website (see www.eurl-ar.eu). 
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Antimicrobial susceptibility testing 
The strains should be tested for susceptibility to the antimicrobials listed in Tables 1, 2 and 3, using 
the method implemented in your laboratory for performing monitoring for EFSA and applying the 
interpretative criteria listed below.  
Participants should perform minimum inhibitory concentration (MIC) determination using the 
methods stated in the Commission Implementing Decision 2013/652/EU. For staphylococci, MIC 
methods should be used as well, according to the EFSA recommendations and the antimicrobials to 
test are those stated under the EFSA technical specifications (see Table 3). For interpretation of the 
results, use the cut-off values listed in Tables 1, 2, 3 and 4 in this document. These values (except 
where indicated) represent the current epidemiological cut-off values developed by EUCAST 
(www.eucast.org), and allow categorisation of bacterial isolates into two categories: resistant or 
susceptible. A categorisation as intermediate is not accepted.  
Participants will not be allowed to use disk diffusion as the current regulation and recommendations 
only focus on MIC testing. 
 
3.1.1 E. coli  
Table 1. Antimicrobials recommended for AST of Escherichia coli and interpretative criteria 
according to table 1 in Commission Implementing Decision 2013/652/EU 
 
Antimicrobials for E. coli MIC (g/mL) R is > 
Ampicillin, AMP 8 
Azithromycin, AZI 16* 
Cefotaxime, FOT 0.25  
Ceftazidime, TAZ 0.5  
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 0.064  
Colistin, COL 2 
Gentamicin, GEN 2 
Meropenem, MERO 0.125 
Nalidixic acid, NAL 16 
Sulfamethoxazole, SMX 64 
Tetracycline, TET 8 
Tigecycline, TGC 0.5** 
Trimethoprim, TMP 2 
* Tentative ECOFF  
** EUCAST.org 
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Plasmid-mediated quinolone resistance  
When performing antimicrobial susceptibility testing of E. coli, the interpretative criteria listed in 
Table 1 for results obtained by MIC-determination should allow detection of plasmid-mediated 
quinolone-resistant test strains.  
Beta-lactam resistance 
Confirmatory tests for ESBL production are mandatory on all strains resistant to cefotaxime 
(FOT), ceftazidime (TAZ) and/or meropenem and should be performed by testing the second panel 




Table 2. Antimicrobials recommended for additional AST of Escherichia coli resistant to 
cefotaxime, ceftazidime or meropenem and interpretative criteria according to table 4 in 
Commission Implementing Decision 2013/652/EU 
 
Antimicrobials for E. coli MIC (g/mL) R is > 
Cefepime, FEP 0.125 
Cefotaxime, FOT  0.25 
Cefotaxime + clavulanic acid (F/C) Not applicable 
Cefoxitin, FOX 8 
Ceftazidime, TAZ 0.5 
Ceftazidime+ clavulanic acid (T/C) Not applicable 
Ertapenem, ETP 0.064 
Imipenem, IMI 0.5 
Meropenem, MERO 0.125 
Temocillin, TRM >32* 
*Tentative ECOFF  
Confirmatory test for ESBL production requires use of both cefotaxime (FOT) and ceftazidime 
(TAZ) alone and in combination with a -lactamase inhibitor (clavulanic acid). Synergy is defined 
either as i) a ≥ 3 twofold concentration decrease in an MIC for either antimicrobial agent tested in 
combination with clavulanic acid vs. the MIC of the agent when tested alone (MIC FOT : FOT/CL 
or TAZ : TAZ/CL ratio  8) (CLSI M100 Table 3A, Tests for ESBLs). The presence of synergy 
indicates ESBL production.  
Confirmatory test for carbapenemase production requires the testing of meropenem (MERO).  
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Detection of AmpC-type beta-lactamases can be performed by testing the bacterium for 
susceptibility to cefoxitin (FOX). Resistance to FOX could indicate the presence of an AmpC-type 
beta-lactamase. 
The classification of the phenotypic results should be based on the most recent EFSA 
recommendations (EURL-AR Workshop 2016, http://www.crl-ar.eu/data/images/ws_april-
2016/f11_efsa_criteria.pdf and in the appendix to this protocol). 
 
3.1.2 Enterococci  
Table 3. Antimicrobials recommended for AST of Enterococcus spp. and interpretative criteria 
according to table 3 in Commission Implementing Decision 2013/652/EU 
 
Antimicrobials for enterococci MIC (g/mL) R is > 
MIC (g/mL) 
R is > 
 E. faecium E. faecalis 
Ampicillin, AMP 4 4 
Chloramphenicol, CHL 32 32 
Ciprofloxacin, CIP 4 4 
Daptomycin, DAP 4 4 
Erythromycin, ERY 4 4 
Gentamicin, GEN 32 32 
Linezolid, LZD 4 4 
Quinupristin-dalfopristin (Synercid), SYN 4* Not applicable 
Teicoplanin, TEI 2 2 
Tetracycline, TET 4 4 
Tigecycline, TGC 0.25 0.25 
Vancomycin, VAN 4 4 
*DANMAP 2009 (www.danmap.org)  
 
Identification of Enterococcus spp. 
Species identification of enterococci must be performed by the NRLs using in-house methods or 
adopting the protocol available on the EURL-AR website under: www.eurl-ar.eu/233-
protocols.htm.  
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3.1.3 Staphylococci  
Table 4. Antimicrobials recommended for AST of Staphylococcus aureus and interpretative criteria 
according to EFSA technical specifications (EFSA Journal 2012;10(10):2897) 
 
Antimicrobials for S. aureus MIC (g/mL) R is > 
Cefoxitin, FOX 4 
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 1 
Clindamycin, CLN 0.25 
Erythromycin, ERY 1 
Gentamicin, GEN 2 
Linezolid, LZD 4 
Mupirocin, MUP 1 
Quinupristin-dalfopristin (Synercid), SYN 1 
Sulfamethoxazole, SMX 128 
Sulfamethoxazole+Trimethoprim, SXT 0.5 
Tetracycline, TET 1 
Tiamulin, TIA 2 
Trimethoprim, TMP 2 
Vancomycin, VAN 2 
 
Identification of MRSA 
Confirmation of mecA and/or mecC presence is mandatory in this EQAS. For this purpose, you 
are recommended to use the PCR method protocol recommended by the EURL-AR (www.eurl-
ar.eu/233-protocols.htm) and upload the result as ‘positive’ or ‘negative’.  
 
4 REPORTING OF RESULTS AND EVALUATION 
Please write your results in the test forms, and enter your results into the interactive web database. 
In addition, we kindly ask you to report in the database the tested MIC range for the staphylococci 
tests (for this organism only, as it is not included the Commission Implementing Decision 
2013/652/EU). Finally, if you did not use the cut-off values recommended in the protocol for 
interpretation of Staphylococcus AST results, please report the breakpoints used in the database. 
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4.1 General recommendations for data upload 
We recommend reading carefully the description reported in paragraph 5 before entering your 
results in the web database. Results must be submitted no later than September 2nd, 2016. After 
the deadline when all participants have uploaded results, you will be able to login to the database 
once again, and to view and print an automatically generated report evaluating your results. Results 
in agreement with the expected interpretation are categorised as ‘correct’, while results deviating 
from the expected interpretation are categorised as ‘incorrect’. 
If you experience difficulties in entering your results, please contact us directly.  
All results will be summarised in a report which will be publicly available. The data in the report 
will be presented with laboratory codes. A laboratory code is known to the individual laboratory, 
whereas the complete list of laboratories and their codes is confidential and known only to the 
EURL-AR and the EU Commission. All conclusions will be public. 
If you have questions, please do not hesitate to contact the EQAS Coordinator: 
Susanne Karlsmose Pedersen 
National Food Institute 
Technical University of Denmark 
Søltofts Plads, Building 221, DK-2800 Lyngby 
Denmark 
Tel: +45 3588 6601 
Fax: +45 3588 6341 
E-mail: suska@food.dtu.dk 
 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read carefully this paragraph before entering the web page. 
Remember that you need by your side the completed test forms and the breakpoint values you used.  
Enter the EURL-AR EQAS 2016 start web page (http://eurl-ar.food.dtu.dk), write your username 
and password in lower-cases and press enter. Your username and password are indicated in the 
letter accompanying your strains. Do not hesitate to contact us if you experience problems with the 
login. 
You can browse back and forth by using the Home or back keys, but please remember to save your 
inputs before. 
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5.1 AST of E. coli, enterococci and staphylococci 
Click on either “E. coli”, “enterococci” or “staphylococci” for input of test results based on the 
results you are going to upload.  
Click on "Start of Data Entry - Methods and Breakpoints”. 
In the next page, you can navigate among fields with the Tab-key and the mouse.  
Complete the fields related to the method used for antimicrobial susceptibility testing and the brand 
of MIC trays, etc.  
Click on “save” and then go back using the tab “home” and enter another test page to upload 
results.  
In the data entry pages, enter the obtained values and the interpretation (R, resistant or S, 
susceptible) for each E. coli, enterococcus and staphylococcus strain. 
For E. coli strains, remember to report also the results for the ESBL detection tests. 
For S. aureus strains, remember to report also the results for presence/absence of methicillin 
resistance. 
If you did not test for susceptibility to a given antimicrobial, please leave the field empty. 
Click on “save“ and then go back using the tab “home” and enter another test page to upload 
results.  
When uploading data on the reference strains, please enter MIC values in µg/ml. Remember to use 
the operator keys to show symbols like “equal to”, etc. 
Click on “save“. 
Review the input pages by browsing through the pages and make corrections if necessary. 
Remember to save a page if you make corrections. If you press home to leave a page without saving 
changes, you will see an error screen. In this case, click on “save“ to save your results, browse back 
to the page and then continue. 
Please complete the evaluation form. 
Before approving your input, please be sure that you have filled in all the relevant fields because 
YOU CAN ONLY APPROVE ONCE!  The approval blocks your data entry in the interactive 
database. 
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Please refer to the full presentation at http://www.crl-ar.eu/data/images/ws_april-
2016/f11_efsa_criteria.pdf  
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Antimicrobial susceptibility testing of Escherichia coli, enterococci 
and staphylococci 
TEST FORMS 
Name:       
Name of laboratory: 
Name of institute:       
City:       





Appendices EURL-AR EQAS EC-ENT-ST 2016 Page 17 of 81
EU Reference Laboratory for Antimicrobial Resistance  








TEST FORMS METHODS - Enterococci 
Which method did you use for antimicrobial susceptibility testing of enterococci in this EQAS: 
  MIC – Microtitre    
  MIC – Agar dilution 
 Brand:                            
 
How many Enterococcus spp. isolates does your laboratory annually isolate:       
 
How many Enterococcus spp. isolates does your laboratory annually test for antimicrobial 
susceptibility by a MIC method:       
 
Which method was followed for the preparation of the inoculum? Please describe: 
 Which standard was followed (TREK, CLSI…)       
 Which solvent was used for the preparation of the 0.5 McFarland solution (water, saline)       
 Please describe in detail how you prepared the dilution of the inoculum (including the volume in 
final MH-dilution and intended dilution level; e.g. diluted 1:1000 by adding 10µl of 0.5 
McFarland solution in 10ml MH broth, for an expected inoculum of 1*105 CFU/ml)       
 
Comments or additional information:       
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TEST FORMS METHODS - Staphylococci 
Which method did you use for antimicrobial susceptibility testing of staphylococci in this EQAS: 
  MIC – Microtitre    
  MIC – Agar dilution 
 Brand:                            
 
How many Staphylococcus spp. isolates does your laboratory annually isolate:       
How many Staphylococcus spp. isolates does your laboratory annually test for antimicrobial 
susceptibility by a MIC method:       
Which method was followed for the preparation of the inoculum? Please describe: 
 Which standard was followed (TREK, CLSI…)       
 Which solvent was used for the preparation of the 0.5 McFarland solution (water, saline)       
 Please describe in detail how you prepared the dilution of the inoculum (including the volume in 
final MH-dilution and intended dilution level; e.g. diluted 1:1000 by adding 10µl of 0.5 
McFarland solution in 10ml MH broth, for an expected inoculum of 1*105 CFU/ml)       
 
Comments or additional information:       
Antimicrobial  General information 
 










Cefoxitin, FOX        ≤             ≥       
Chloramphenicol, CHL       ≤             ≥       
Ciprofloxacin, CIP        ≤             ≥       
Clindamycin, CLN       ≤             ≥       
Erythromycin, ERY        ≤             ≥       
Gentamicin, GEN        ≤             ≥       
Linezolid, LZD       ≤             ≥       
Mupirocin, MUP       ≤             ≥       
Quin.-Dalf. (Synercid), SYN         ≤             ≥       
Sulfamethoxazole, SMX        ≤             ≥       
Sulfamethoxazole + 
trimethoprim, SXT 
      ≤             ≥       
Tetracycline, TET        ≤             ≥       
Tiamulin (TIA)       ≤             ≥       
Trimethoprim, TMP        ≤             ≥       
Vancomycin, VAN       ≤             ≥       
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TEST FORMS METHODS – Escherichia coli       
 
Which method did you use for antimicrobial susceptibility testing of E. coli in this EQAS: 
  MIC – Microtitre    
  MIC – Agar dilution 
 
 Brand:                            
 
 Incubation conditions:      °C/     h 
 
How many E. coli isolates does your laboratory annually isolate:       
 
How many E. coli isolates does your laboratory annually test for antimicrobial susceptibility by a 
MIC method:       
 
Which method was followed for the preparation of the inoculum? Please describe: 
 Which standard was followed (TREK, CLSI…)       
 Which solvent was used for the preparation of the 0.5 McFarland solution (water, saline)       
 Please describe in detail how you prepared the dilution of the inoculum (including the volume in 
final MH-dilution and intended dilution level; e.g. diluted 1:1000 by adding 10µl of 0.5 
McFarland solution in 10ml MH broth, for an expected inoculum of 1*105 CFU/ml)       
 
Comments or additional information:       
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TEST FORM - Enterococci                                                            
 
Strain Antimicrobial  Results and interpretation 
 
> 







 E. faecium 
 
 E. faecalis 
Ampicillin AMP                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Daptomycin, DAP                    
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                    
Quin.-Dalf. (Synercid), SYN                     
Teicoplanin, TEI                   
Tetracycline, TET                    
Tigecycline, TGC                   
Vancomycin, VAN                    
 
Strain Antimicrobial  Results and interpretation 
 
> 







 E. faecium 
 
 E. faecalis 
Ampicillin AMP                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Daptomycin, DAP                    
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                    
Quin.-Dalf. (Synercid), SYN                     
Teicoplanin, TEI                   
Tetracycline, TET                    
Tigecycline, TGC                   
Vancomycin, VAN                    
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TEST FORM - Enterococci                                                            
 
Strain Antimicrobial  Results and interpretation 
 
> 







 E. faecium 
 
 E. faecalis 
Ampicillin AMP                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Daptomycin, DAP                    
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                    
Quin.-Dalf. (Synercid), SYN                     
Teicoplanin, TEI                   
Tetracycline, TET                    
Tigecycline, TGC                   
Vancomycin, VAN                    
 
Strain Antimicrobial  Results and interpretation 
 
> 







 E. faecium 
 
 E. faecalis 
Ampicillin AMP                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Daptomycin, DAP                    
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                    
Quin.-Dalf. (Synercid), SYN                     
Teicoplanin, TEI                   
Tetracycline, TET                    
Tigecycline, TGC                   
Vancomycin, VAN                    
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TEST FORM - Enterococci                                                            
 
Strain Antimicrobial  Results and interpretation 
 
> 







 E. faecium 
 
 E. faecalis 
Ampicillin AMP                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Daptomycin, DAP                    
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                    
Quin.-Dalf. (Synercid), SYN                     
Teicoplanin, TEI                   
Tetracycline, TET                    
Tigecycline, TGC                   
Vancomycin, VAN                    
 
Strain Antimicrobial  Results and interpretation 
 
> 







 E. faecium 
 
 E. faecalis 
Ampicillin AMP                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Daptomycin, DAP                    
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                    
Quin.-Dalf. (Synercid), SYN                     
Teicoplanin, TEI                   
Tetracycline, TET                    
Tigecycline, TGC                   
Vancomycin, VAN                    
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TEST FORM - Enterococci                                                            
 
Strain Antimicrobial  Results and interpretation 
 
> 







 E. faecium 
 
 E. faecalis 
Ampicillin AMP                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Daptomycin, DAP                    
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                    
Quin.-Dalf. (Synercid), SYN                     
Teicoplanin, TEI                   
Tetracycline, TET                    
Tigecycline, TGC                   
Vancomycin, VAN                    
 
Strain Antimicrobial  Results and interpretation 
 
> 







 E. faecium 
 
 E. faecalis 
Ampicillin AMP                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Daptomycin, DAP                    
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                    
Quin.-Dalf. (Synercid), SYN                     
Teicoplanin, TEI                   
Tetracycline, TET                    
Tigecycline, TGC                   
Vancomycin, VAN                    
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TEST FORM - Enterococci                                                          
 






Ampicillin, AMP        
Chloramphenicol, CHL          
Ciprofloxacin, CIP          
Daptomycin, DAP       
Erythromycin, ERY        
Gentamicin, GEN        
Linezolid, LZD        
Quinupristin-Dalfopristin (Synercid), SYN       
Teicoplanin, TEI       
Tetracycline, TET        
Tigecycline, TIG       
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TEST FORMS - Staphylococci  
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
S. aureus 
 
EURL ST 10.1 
Cefoxitin, FOX                   
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                    
Clindamycin, CLN                   
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                   
Mupirocin, MUP                   
Quinu-dalfopristin (Synercid), SYN                   
Sulfamethoxazole, SMX                    
Sulfamethoxazole+Trimethoprim, SXT                   
Tetracycline, TET                    
Tiamulin, TIA                   
Trimethoprim, TMP                    
Vancomycin, VAN                   
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TEST FORMS - Staphylococci  
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
S. aureus 
 
EURL ST 10.2 
Cefoxitin, FOX                   
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                    
Clindamycin, CLN                   
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                   
Mupirocin, MUP                   
Quinu-dalfopristin (Synercid), SYN                   
Sulfamethoxazole, SMX                    
Sulfamethoxazole+Trimethoprim, SXT                   
Tetracycline, TET                    
Tiamulin, TIA                   
Trimethoprim, TMP                    
Vancomycin, VAN                   
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TEST FORMS - Staphylococci  
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
S. aureus 
 
EURL ST 10.3 
Cefoxitin, FOX                   
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                    
Clindamycin, CLN                   
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                   
Mupirocin, MUP                   
Quinu-dalfopristin (Synercid), SYN                   
Sulfamethoxazole, SMX                    
Sulfamethoxazole+Trimethoprim, SXT                   
Tetracycline, TET                    
Tiamulin, TIA                   
Trimethoprim, TMP                    
Vancomycin, VAN                   
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TEST FORMS - Staphylococci  
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
S. aureus 
 
EURL ST 10.4 
Cefoxitin, FOX                   
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                    
Clindamycin, CLN                   
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                   
Mupirocin, MUP                   
Quinu-dalfopristin (Synercid), SYN                   
Sulfamethoxazole, SMX                    
Sulfamethoxazole+Trimethoprim, SXT                   
Tetracycline, TET                    
Tiamulin, TIA                   
Trimethoprim, TMP                    
Vancomycin, VAN                   
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TEST FORMS - Staphylococci  
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
S. aureus 
 
EURL ST 10.5 
Cefoxitin, FOX                   
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                    
Clindamycin, CLN                   
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                   
Mupirocin, MUP                   
Quinu-dalfopristin (Synercid), SYN                   
Sulfamethoxazole, SMX                    
Sulfamethoxazole+Trimethoprim, SXT                   
Tetracycline, TET                    
Tiamulin, TIA                   
Trimethoprim, TMP                    
Vancomycin, VAN                   
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TEST FORMS - Staphylococci  
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
S. aureus 
 
EURL ST 10.6 
Cefoxitin, FOX                   
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                    
Clindamycin, CLN                   
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                   
Mupirocin, MUP                   
Quinu-dalfopristin (Synercid), SYN                   
Sulfamethoxazole, SMX                    
Sulfamethoxazole+Trimethoprim, SXT                   
Tetracycline, TET                    
Tiamulin, TIA                   
Trimethoprim, TMP                    
Vancomycin, VAN                   
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TEST FORMS - Staphylococci  
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
S. aureus 
 
EURL ST 10.7 
Cefoxitin, FOX                   
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                    
Clindamycin, CLN                   
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                   
Mupirocin, MUP                   
Quinu-dalfopristin (Synercid), SYN                   
Sulfamethoxazole, SMX                    
Sulfamethoxazole+Trimethoprim, SXT                   
Tetracycline, TET                    
Tiamulin, TIA                   
Trimethoprim, TMP                    
Vancomycin, VAN                   
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TEST FORMS - Staphylococci  
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
S. aureus 
 
EURL ST 10.8 
Cefoxitin, FOX                   
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                    
Clindamycin, CLN                   
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                   
Mupirocin, MUP                   
Quinu-dalfopristin (Synercid), SYN                   
Sulfamethoxazole, SMX                    
Sulfamethoxazole+Trimethoprim, SXT                   
Tetracycline, TET                    
Tiamulin, TIA                   
Trimethoprim, TMP                    
Vancomycin, VAN                   
 
 Methicillin resistance (MRSA)  Positive             Negative 
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TEST FORM - Staphylococci                                                         
 






Cefoxitin, FOX       
Chloramphenicol, CHL         
Ciprofloxacin, CIP         
Clindamycin, CLN       
Erythromycin, ERY        
Gentamicin, GEN        
Linezolid, LZD       
Mupirocin, MUP       
Quinupristin-dalfopristin (Synercid), SYN       
Sulfamethoxazole, SMX        
Sulfamethoxazole + trimethoprim, SXT       
Tetracycline, TET       
Tiamulin, TIA       
Trimethoprim, TMP       
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Page 19 of 27 
G00-06-001/28.06.2016 
 
TEST FORM – E. coli 
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 10.1 
Ampicillin, AMP                         
Azithromycin, AZT                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) should be 
included for testing in the second panel confirmatory tests for ESBL or carbapenemase production. 
See further description of confirmatory tests in the protocol section ‘3.1.1 E. coli’. 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 10.1 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):       
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Page 20 of 27 
G00-06-001/28.06.2016 
 
TEST FORM – E. coli                                                            
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 10.2 
Ampicillin, AMP                         
Azithromycin, AZT                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) should be 
included for testing in the second panel confirmatory tests for ESBL or carbapenemase production. 
See further description of confirmatory tests in the protocol section ‘3.1.1E. coli’.                              
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 10.2 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):       
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Page 21 of 27 
G00-06-001/28.06.2016 
 
TEST FORM – E. coli 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC10.3 
Ampicillin, AMP                         
Azithromycin, AZT                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) should be 
included for testing in the second panel confirmatory tests for ESBL or carbapenemase production. 
See further description of confirmatory tests in the protocol section ‘3.1.1 E. coli’.                             
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 10.3 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):       
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Page 22 of 27 
G00-06-001/28.06.2016 
 
TEST FORM – E. coli 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 10.4 
Ampicillin, AMP                         
Azithromycin, AZT                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) should be 
included for testing in the second panel confirmatory tests for ESBL or carbapenemase production. 
See further description of confirmatory tests in the protocol section ‘3.1.1 E. coli’.                             
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 10.4 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):       
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Page 23 of 27 
G00-06-001/28.06.2016 
 
TEST FORM – E. coli 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 10.5 
Ampicillin, AMP                         
Azithromycin, AZT                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) should be 
included for testing in the second panel confirmatory tests for ESBL or carbapenemase production. 
See further description of confirmatory tests in the protocol section ‘3.1.1 E. coli’.                             
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 10.5 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):       
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Page 24 of 27 
G00-06-001/28.06.2016 
 
TEST FORM – E. coli 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 10.6 
Ampicillin, AMP                         
Azithromycin, AZT                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) should be 
included for testing in the second panel confirmatory tests for ESBL or carbapenemase production. 
See further description of confirmatory tests in the protocol section ‘3.1.1 E. coli’.                             
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 10.6 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive carbapenemase 
 
 Other phenotype 
 Susceptible  
Comments (include optional genotype or other results):       
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Page 25 of 27 
G00-06-001/28.06.2016 
 
TEST FORM – E. coli 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 10.7 
Ampicillin, AMP                         
Azithromycin, AZT                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) should be 
included for testing in the second panel confirmatory tests for ESBL or carbapenemase production. 
See further description of confirmatory tests in the protocol section ‘3.1.1 E. coli’.                             
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 10.7 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):       
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G00-06-001/28.06.2016 
 
TEST FORM – E. coli 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 10.8 
Ampicillin, AMP                         
Azithromycin, AZT                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) should be 
included for testing in the second panel confirmatory tests for ESBL or carbapenemase production. 
See further description of confirmatory tests in the protocol section ‘3.1.1 E. coli’.                             
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 10.8 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):       
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G00-06-001/28.06.2016 
 
TEST FORM – E. coli                                                           
 










Ampicillin, AMP        
Azithromycin, AZT       
Cefotaxime, FOT       
Ceftazidime, TAZ       
Chloramphenicol, CHL       
Ciprofloxacin, CIP       
Colistin, COL       
Gentamicin, GEN       
Meropenem, MERO       
Nalidixic acid, NAL       
Sulfamethoxazole, SMX       
Tetracycline, TET       
Tigecycline, TGC       
Trimethoprim, TMP       
2nd panel Cefepime, FEP       
Cefotaxime, FOT       
Cefotaxime + clavulanic acid (F/C)       
Cefoxitin, FOX       
Ceftazidime, TAZ       
Ceftazidime+ clavulanic acid (T/C)       
Ertapenem, ETP       
Imipenem, IMI       
Meropenem, MERO       








Instructions for Opening and Reviving Lyophilised Cultures                                                         G00-06-001/01.12.2014 
Page 1 of 1 




Instructions adjusted from Czech Collection of Microorganisms (CCM) document ’Instructions for 
Opening and Reviving of Freeze-Dried Bacteria and Fungi’ available on http://www.sci.muni.cz.  
Lyophilised cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule. All instructions given below should be followed closely to ensure the safety of the person 
who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture on the label inside the ampoule 
b. Make a file cut on the ampoule near the middle of the plug (see Figure 1) 
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool from 
just below the plug to the pointed end 
d. Apply a red-hot glass rod to the file cut to crack the glass and allow air to enter slowly into 
the ampoule 
e. Remove the pointed end of the ampoule into disinfectant 
f. Add about 0.3 ml appropriate broth to the dried suspension using a sterile Pasteur pipette 
and mix carefully to avoid creating aerosols. Transfer the contents to one or more suitable 
solid and /or liquid media 
g. Incubate the inoculated medium at appropriate conditions for several days 
h. Autoclave or disinfect effectively the used Pasteur pipette, the plug and all the remains of 
the original ampoule before discarding 
Notes:  
 Cultures should be grown on media and under conditions as recommended in the CCM 
catalogue (see http://www.sci.muni.cz) 
 Cultures may need at least one subculturing before they can be optimally used in experiments 








Figure 1: from CCM document ’Instructions for Opening 
and Reviving of Freeze-Dried Bacteria and Fungi’ available 
on http://www.sci.muni.cz 







Subculture and Maintenance of QC strains                                                                                                                     G00-06-001/01.12.2014  




SUBCULTURE AND MAINTENANCE OF    
QUALITY CONTROL STRAINS 
1.1 Purpose 
Improper storage and repeated subculturing of bacteria can produce alterations in antimicrobial 
susceptibility test results. The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) 
has published a guideline for Quality Control (QC) stock culture maintenance to ensure consistent 
antimicrobial susceptibility test results. 
1.2 References 
M100-S24, January 2014 (Performance Standards for Antimicrobial Susceptibility Testing) 
M7-A9, January 2012 (Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That 
Grow Aerobically; Approved Standard) 
1.3 Definition of Terms 
Reference Culture: A reference culture is a microorganism preparation that is acquired from a 
culture type collection.  
Reference Stock Culture: A reference stock culture is a microorganism preparation that is derived 
from a reference culture. Guidelines and standards outline how reference stock cultures must be 
processed and stored.  
Working Stock Cultures: A working stock culture is growth derived from a reference stock culture. 
Guidelines and standards outline how working stock cultures must be processed and how often they 
can be subcultured.  
Subcultures (Passages): A subculture is simply the transfer of established microorganism growth on 
media to fresh media. The subsequent growth on the fresh media constitutes a subculture or 
passage. Growing a reference culture or reference stock culture from its preserved status (frozen or 
lyophilized) is not a subculture. The preserved microorganism is not in a stage of established 
growth until it is thawed or hydrated and grown for the first time 
1.4 Important Considerations 
 Do not use disc diffusion strains for MIC determination. 
 Obtain QC strains from a reliable source such as ATCC 
 CLSI requires that QC be performed either on the same day or weekly (only after 30 day QC 
validation) 
 Any changes in materials or procedure must be validated with QC before implemented 
 For example: Agar and broth methods may give different QC ranges for drugs such as 
glycopeptides, aminoglycosides and macrolides 
 Periodically perform colony counts to check the inoculum preparation procedure 
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 Ideally, test values should be in the middle of the acceptable range 
 Graphing QC data points over time can help identify changes in data helpful for 
troubleshooting problems 
1.5 Storage of Reference Strains 
Preparation of stock cultures 
 Use a suitable stabilizer such as 50% fetal calf serum in broth, 10-15% glycerol in tryptic 
soy broth, defibrinated sheep blood or skim milk to prepare multiple aliquots. 
 Store at -20°C, -70°C or liquid nitrogen. (Alternatively, freeze dry.) 
 Before using rejuvenated strains for QC, subculture to check for purity and viability. 
Working cultures 
 Set up on agar slants with appropriate medium, store at 4-8°C and subculture weekly. 
 Replace the working strain with a stock culture at least monthly. 
 If a change in the organisms inherent susceptibility occurs, obtain a fresh stock culture or a 
new strain from a reference culture collection e.g. ATCC. 
1.6 Frequency of Testing 
Weekly vs. daily testing  
Weekly testing is possible if the lab can demonstrate satisfactory performance with daily testing as 
follows: 
 Documentation showing reference strain results from 30 consecutive test days were within 
the acceptable range. 
 For each antimicrobial/organism combination, no more than 3 out of 30 MIC values may be 
outside the acceptable range. 
When the above are fulfilled, each quality control strain may be tested once a week and whenever 
any reagent component is changed. 
Corrective Actions  
If an MIC is outside the range in weekly testing, corrective action is required as follows: 
 Repeat the test if there is an obvious error e.g. wrong strain or incubation conditions used 
 If there is no obvious error, return to daily control testing 
The problem is considered resolved only after the reference strain is tested for 5 consecutive days 
and each drug/organism result is within specification on each day. 
If the problem cannot be resolved, continue daily testing until the errors are identified. 
Repeat the 30 days validation before resuming weekly testing.  
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DAILY MIC QC CHART 
 
  Reference: CLSI M7-A9, page 46 
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Reference: CLSI M7-A7, page 40 Reference: CLSI M7-A9, page 47 







Ampicillin AMP 2 8
Azithromycin AZI NA NA
Cefotaxime FOT 0.03 0.12
Ceftazidime TAZ 0.06 0.5
Chloramphenicol CHL 2 8
Ciprofloxacin CIP 0.004 0.015
Colistin COL 0.25 2
Gentamicin GEN 0.25 1
Meropenem MER 0.008 0.06
Nalidixic acid NAL 1 4
Sulfamethoxazole SMX 8 32
Tetracycline TET 0.5 2
Tigecycline TGC 0.03 0.25







Cefepime FEP 0.015 0.12
Cefotaxime/clavulanic acid F/C NA na
Cefotaxime FOT 0.03 0.12
Cefoxitin FOX 2 8
Ceftazidime TAZ 0.06 0.5
Ceftazidime/clavulanic acid T/C NA NA
Ertapenem ETP 0.004 0.015
Imipenem IMI 0.06 0.25
Meropenem MER 0.008 0.06











Cefoxitin FOX 1 4
Chloramphenicol CHL 2 16
Ciprofloxacin CIP 0.12 0.5
Clindamycin CLN 0.06 0.25
Erythromycin ERY 0.25 1
Gentamicin GEN 0.12 1
Linezolid LZD 1 4
Mupirocin MUP NA NA
Quinupristin‐dalfopristin SYN 0.25 1
Sulfamethoxazole SMX 32 128
Sulfamethoxazole‐trimethoprim SXT 0 0.5
Tetracycline TET 0.12 1
Tiamulin TIA NA NA
Trimethoprim TMP 1 4







Ampicillin AMP 0.5 2
Chloramphenicol CHL 4 16
Ciprofloxacin CIP 0.25 2
Daptomycin DAP 1* 4*
Erythromycin ERY 1 4
Gentamicin GEN 4 16
Linezolid LZD 1 4
Quinupristin‐dalfopristin SYN 2 8
Teicoplanin TEI 0.25 1
Tetracycline TET 8 32
Tigecycline TGC 0.03 0.12
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Enterococcus faecalis  ATCC 29212 results
Lab. code Antimicrobial Operator Read_value Min Value Max Value Score
2 Ampicillin = 1 0.5 2 1
2 Chloramphenicol = 8 4 16 1
2 Ciprofloxacin = 0.5 0.25 2 1
2 Daptomycin = 2 1 4 1
2 Erythromycin = 2 1 4 1
2 Gentamicin = 16 4 16 1
2 Linezolid = 2 1 4 1
2 Teicoplanin <= 0.5 0.25 1 1
2 Tetracycline = 32 8 32 1
2 Tigecycline = 0.12 0.03 0.12 1
2 Vancomycin = 4 1 4 1
9 Ampicillin = 1 0.5 2 1
9 Chloramphenicol = 8 4 16 1
9 Ciprofloxacin = 0.5 0.25 2 1
9 Daptomycin = 2 1 4 1
9 Erythromycin = 2 1 4 1
9 Gentamicin <= 8 4 16 1
9 Linezolid = 2 1 4 1
9 Teicoplanin <= 0.5 0.25 1 1
9 Tetracycline = 16 8 32 1
9 Tigecycline = 0.06 0.03 0.12 1
9 Vancomycin = 2 1 4 1
11 Ampicillin <= 0.5 0.5 2 1
11 Chloramphenicol = 8 4 16 1
11 Ciprofloxacin = 1 0.25 2 1
11 Daptomycin = 1 1 4 1
11 Erythromycin = 2 1 4 1
11 Gentamicin = 16 4 16 1
11 Linezolid = 2 1 4 1
11 Teicoplanin <= 0.5 0.25 1 1
11 Tetracycline = 16 8 32 1
11 Tigecycline = 0.12 0.03 0.12 1
11 Vancomycin = 4 1 4 1
12 Ampicillin = 1 0.5 2 1
12 Chloramphenicol <= 4 4 16 1
12 Ciprofloxacin = 1 0.25 2 1
12 Daptomycin = 2 1 4 1
12 Erythromycin = 2 1 4 1
12 Gentamicin <= 8 4 16 1
12 Linezolid = 2 1 4 1
12 Teicoplanin <= 0.5 0.25 1 1
12 Tetracycline = 32 8 32 1
12 Tigecycline = 0.12 0.03 0.12 1
12 Vancomycin = 2 1 4 1
16 Ampicillin = 1 0.5 2 1
16 Chloramphenicol = 8 4 16 1
16 Ciprofloxacin = 1 0.25 2 1
16 Daptomycin = 2 1 4 1
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16 Erythromycin = 2 1 4 1
16 Gentamicin = 16 4 16 1
16 Linezolid = 2 1 4 1
16 Teicoplanin <= 0.5 0.25 1 1
16 Tetracycline = 32 8 32 1
16 Tigecycline = 0.12 0.03 0.12 1
16 Vancomycin = 2 1 4 1
17 Ampicillin = 1 0.5 2 1
17 Chloramphenicol = 8 4 16 1
17 Ciprofloxacin = 1 0.25 2 1
17 Daptomycin = 2 1 4 1
17 Erythromycin = 2 1 4 1
17 Gentamicin = 16 4 16 1
17 Linezolid = 2 1 4 1
17 Teicoplanin <= 0.5 0.25 1 1
17 Tetracycline = 32 8 32 1
17 Tigecycline = 0.12 0.03 0.12 1
17 Vancomycin = 4 1 4 1
19 Ampicillin = 1 0.5 2 1
19 Chloramphenicol = 8 4 16 1
19 Ciprofloxacin = 0.5 0.25 2 1
19 Daptomycin = 2 1 4 1
19 Erythromycin = 2 1 4 1
19 Gentamicin = 16 4 16 1
19 Linezolid = 2 1 4 1
19 Teicoplanin <= 0.5 0.25 1 1
19 Tetracycline = 32 8 32 1
19 Tigecycline = 0.12 0.03 0.12 1
19 Vancomycin = 2 1 4 1
20 Ampicillin = 1 0.5 2 1
20 Chloramphenicol = 8 4 16 1
20 Ciprofloxacin = 1 0.25 2 1
20 Daptomycin = 4 1 4 1
20 Erythromycin = 2 1 4 1
20 Gentamicin <= 8 4 16 1
20 Linezolid = 2 1 4 1
20 Teicoplanin <= 0.5 0.25 1 1
20 Tetracycline = 16 8 32 1
20 Tigecycline = 0.12 0.03 0.12 1
20 Vancomycin = 4 1 4 1
22 Ampicillin = 1 0.5 2 1
22 Chloramphenicol = 8 4 16 1
22 Ciprofloxacin = 0.25 0.25 2 1
22 Daptomycin = 2 1 4 1
22 Erythromycin = 2 1 4 1
22 Gentamicin <= 8 4 16 1
22 Linezolid = 2 1 4 1
22 Tetracycline = 16 8 32 1
22 Tigecycline = 0.06 0.03 0.12 1
22 Vancomycin = 2 1 4 1
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23 Ampicillin <= 0.5 0.5 2 1
23 Chloramphenicol <= 4 4 16 1
23 Ciprofloxacin = 0.5 0.25 2 1
23 Daptomycin = 1 1 4 1
23 Erythromycin = 2 1 4 1
23 Gentamicin <= 8 4 16 1
23 Linezolid = 1 1 4 1
23 Teicoplanin <= 0.5 0.25 1 1
23 Tetracycline = 16 8 32 1
23 Tigecycline = 0.06 0.03 0.12 1
23 Vancomycin <= 1 1 4 1
25 Ampicillin = 1 0.5 2 1
25 Chloramphenicol = 8 4 16 1
25 Ciprofloxacin = 1 0.25 2 1
25 Daptomycin = 2 1 4 1
25 Erythromycin <= 2 1 4 1
25 Gentamicin = 16 4 16 1
25 Linezolid = 2 1 4 1
25 Teicoplanin <= 0.5 0.25 1 1
25 Tetracycline = 32 8 32 1
25 Tigecycline = 0.12 0.03 0.12 1
25 Vancomycin = 4 1 4 1
26 Ampicillin = 1 0.5 2 1
26 Chloramphenicol <= 4 4 16 1
26 Ciprofloxacin = 1 0.25 2 1
26 Daptomycin = 4 1 4 1
26 Erythromycin = 2 1 4 1
26 Gentamicin <= 8 4 16 1
26 Linezolid = 2 1 4 1
26 Teicoplanin <= 0.5 0.25 1 1
26 Tetracycline = 16 8 32 1
26 Tigecycline = 0.12 0.03 0.12 1
26 Vancomycin <= 1 1 4 1
29 Ampicillin = 0.5 0.5 2 1
29 Chloramphenicol = 8 4 16 1
29 Ciprofloxacin = 2 0.25 2 1
29 Daptomycin = 4 1 4 1
29 Erythromycin = 4 1 4 1
29 Gentamicin = 8 4 16 1
29 Linezolid = 2 1 4 1
29 Teicoplanin = 1 0.25 1 1
29 Tetracycline = 16 8 32 1
29 Tigecycline = 0.03 0.03 0.12 1
29 Vancomycin = 4 1 4 1
30 Ampicillin = 2 0.5 2 1
30 Chloramphenicol = 4 4 16 1
30 Ciprofloxacin = 1 0.25 2 1
30 Daptomycin = 1 1 4 1
30 Erythromycin = 2 1 4 1
30 Gentamicin <= 8 4 16 1
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30 Linezolid = 2 1 4 1
30 Teicoplanin <= 0.5 0.25 1 1
30 Tetracycline = 16 8 32 1
30 Tigecycline = 0.12 0.03 0.12 1
30 Vancomycin <= 1 1 4 1
33 Ampicillin = 1 0.5 2 1
33 Chloramphenicol = 4 4 16 1
33 Erythromycin = 4 1 4 1
33 Gentamicin = 4 4 16 1
33 Linezolid = 2 1 4 1
33 Tetracycline = 32 8 32 1
33 Vancomycin = 2 1 4 1
34 Ampicillin = 1 0.5 2 1
34 Chloramphenicol = 8 4 16 1
34 Ciprofloxacin = 0.5 0.25 2 1
34 Daptomycin = 2 1 4 1
34 Erythromycin = 4 1 4 1
34 Gentamicin <= 8 4 16 1
34 Linezolid = 2 1 4 1
34 Teicoplanin <= 0.5 0.25 1 1
34 Tetracycline = 32 8 32 1
34 Tigecycline = 0.12 0.03 0.12 1
34 Vancomycin <= 1 1 4 1
36 Ampicillin ‐ 1 0.5 2 1
36 Chloramphenicol <= 4 4 16 1
36 Ciprofloxacin ‐ 0.5 0.25 2 1
36 Daptomycin ‐ 2 1 4 1
36 Erythromycin ‐ 2 1 4 1
36 Gentamicin ‐ 16 4 16 1
36 Linezolid ‐ 2 1 4 1
36 Teicoplanin <= 0.5 0.25 1 1
36 Tetracycline ‐ 16 8 32 1
36 Tigecycline ‐ 0.12 0.03 0.12 1
36 Vancomycin ‐ 2 1 4 1
37 Ampicillin = 1 0.5 2 1
37 Chloramphenicol <= 8 4 16 1
37 Ciprofloxacin = 1 0.25 2 1
37 Erythromycin <= 1 1 4 1
37 Gentamicin <= 8 4 16 1
37 Linezolid = 2 1 4 1
37 Teicoplanin <= 0.5 0.25 1 1
37 Tetracycline = 16 8 32 1
37 Tigecycline = 0.13 0.03 0.12 0
37 Vancomycin = 4 1 4 1
38 Ampicillin = 2 0.5 2 1
38 Chloramphenicol = 8 4 16 1
38 Ciprofloxacin = 0.5 0.25 2 1
38 Daptomycin = 2 1 4 1
38 Erythromycin <= 1 1 4 1
38 Gentamicin <= 8 4 16 1
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38 Linezolid = 2 1 4 1
38 Teicoplanin <= 0.5 0.25 1 1
38 Tetracycline = 16 8 32 1
38 Tigecycline = 0.06 0.03 0.12 1
38 Vancomycin = 4 1 4 1
39 Ampicillin <= 0.5 0.5 2 1
39 Chloramphenicol ‐ 8 4 16 1
39 Ciprofloxacin ‐ 0.25 0.25 2 1
39 Daptomycin ‐ 1 1 4 1
39 Erythromycin ‐ 2 1 4 1
39 Gentamicin <= 8 4 16 1
39 Linezolid ‐ 2 1 4 1
39 Teicoplanin <= 0.5 0.25 1 1
39 Tetracycline ‐ 16 8 32 1
39 Tigecycline ‐ 0.12 0.03 0.12 1
39 Vancomycin ‐ 2 1 4 1
40 Chloramphenicol = 8 4 16 1
40 Ciprofloxacin = 0.5 0.25 2 1
40 Daptomycin = 1 1 4 1
40 Erythromycin = 2 1 4 1
40 Linezolid = 2 1 4 1
40 Tetracycline = 8 8 32 1
40 Tigecycline = 0.06 0.03 0.12 1
40 Vancomycin = 2 1 4 1
41 Ampicillin = 1 0.5 2 1
41 Chloramphenicol = 8 4 16 1
41 Ciprofloxacin = 0.25 0.25 2 1
41 Daptomycin = 1 1 4 1
41 Erythromycin <= 1 1 4 1
41 Gentamicin <= 8 4 16 1
41 Linezolid = 1 1 4 1
41 Teicoplanin <= 0.5 0.25 1 1
41 Tetracycline = 8 8 32 1
41 Tigecycline = 0.06 0.03 0.12 1
41 Vancomycin = 2 1 4 1
42 Ampicillin = 2 0.5 2 1
42 Chloramphenicol = 8 4 16 1
42 Ciprofloxacin = 1 0.25 2 1
42 Daptomycin = 2 1 4 1
42 Erythromycin = 2 1 4 1
42 Gentamicin <= 8 4 16 1
42 Linezolid = 2 1 4 1
42 Teicoplanin <= 0.5 0.25 1 1
42 Tetracycline = 32 8 32 1
42 Tigecycline = 0.06 0.03 0.12 1
42 Vancomycin = 2 1 4 1
45 Ampicillin = 2 0.5 2 1
45 Chloramphenicol <= 4 4 16 1
45 Ciprofloxacin <= 0.12 0.25 2 0
45 Daptomycin <= 0.25 1 4 0
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45 Erythromycin <= 1 1 4 1
45 Gentamicin <= 8 4 16 1
45 Linezolid = 1 1 4 1
45 Teicoplanin <= 0.5 0.25 1 1
45 Tetracycline = 32 8 32 1
45 Tigecycline = 0.25 0.03 0.12 0
45 Vancomycin <= 1 1 4 1
56 Ampicillin = 1 0.5 2 1
56 Chloramphenicol = 8 4 16 1
56 Ciprofloxacin = 0.5 0.25 2 1
56 Daptomycin = 1 1 4 1
56 Erythromycin = 2 1 4 1
56 Gentamicin <= 8 4 16 1
56 Linezolid = 1 1 4 1
56 Teicoplanin <= 0.5 0.25 1 1
56 Tetracycline = 16 8 32 1
56 Tigecycline = 0.06 0.03 0.12 1
56 Vancomycin <= 1 1 4 1
59 Ampicillin = 2 0.5 2 1
59 Chloramphenicol = 8 4 16 1
59 Ciprofloxacin = 0.5 0.25 2 1
59 Daptomycin = 1 1 4 1
59 Erythromycin = 2 1 4 1
59 Gentamicin = 16 4 16 1
59 Linezolid = 2 1 4 1
59 Teicoplanin <= 0.5 0.25 1 1
59 Tetracycline = 32 8 32 1
59 Tigecycline = 0.12 0.03 0.12 1
59 Vancomycin = 2 1 4 1
60 Ampicillin = 1 0.5 2 1
60 Chloramphenicol = 8 4 16 1
60 Ciprofloxacin = 1 0.25 2 1
60 Daptomycin = 2 1 4 1
60 Erythromycin = 2 1 4 1
60 Gentamicin <= 8 4 16 1
60 Linezolid = 2 1 4 1
60 Teicoplanin <= 0.5 0.25 1 1
60 Tetracycline = 16 8 32 1
60 Tigecycline = 0.12 0.03 0.12 1
60 Vancomycin = 4 1 4 1
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Staphylococcus aureus  ATCC 29213 results
Lab. code Antimicrobial Operator Read_value Min Value Max Value Score
2 Cefoxitin = 4 1 4 1
2 Chloramphenicol = 8 2 16 1
2 Ciprofloxacin <= 0.25 0.12 0.5 1
2 Clindamycin <= 0.12 0.06 0.25 1
2 Erythromycin <= 0.25 0.25 1 1
2 Gentamicin <= 1 0.12 1 1
2 Linezolid = 2 1 4 1
2 Sulfamethoxazole <= 64 32 128 1
2 Tetracycline <= 0.5 0.12 1 1
2 Trimethoprim <= 2 1 4 1
2 Vancomycin <= 1 0.5 2 1
9 Cefoxitin = 2 1 4 1
9 Chloramphenicol <= 4 2 16 1
9 Ciprofloxacin <= 0.25 0.12 0.5 1
9 Clindamycin <= 0.12 0.06 0.25 1
9 Erythromycin <= 0.5 0.25 1 1
9 Gentamicin <= 1 0.12 1 1
9 Linezolid = 2 1 4 1
9 Sulfamethoxazole <= 64 32 128 1
9 Tetracycline <= 0.5 0.12 1 1
9 Trimethoprim <= 2 1 4 1
9 Vancomycin <= 1 0.5 2 1
11 Cefoxitin = 4 1 4 1
11 Chloramphenicol = 8 2 16 1
11 Ciprofloxacin = 0.5 0.12 0.5 1
11 Clindamycin = 0.25 0.06 0.25 1
11 Erythromycin = 0.5 0.25 1 1
11 Gentamicin <= 1 0.12 1 1
11 Linezolid = 2 1 4 1
11 Sulfamethoxazole <= 64 32 128 1
11 Tetracycline = 1 0.12 1 1
11 Trimethoprim <= 2 1 4 1
11 Vancomycin <= 1 0.5 2 1
12 Cefoxitin = 4 1 4 1
12 Chloramphenicol = 8 2 16 1
12 Ciprofloxacin <= 0.25 0.12 0.5 1
12 Clindamycin <= 0.12 0.06 0.25 1
12 Erythromycin = 0.5 0.25 1 1
12 Gentamicin <= 1 0.12 1 1
12 Linezolid = 2 1 4 1
12 Sulfamethoxazole <= 64 32 128 1
12 Tetracycline <= 0.5 0.12 1 1
12 Trimethoprim <= 2 1 4 1
12 Vancomycin <= 1 0.5 2 1
17 Cefoxitin = 4 1 4 1
17 Chloramphenicol = 16 2 16 1
17 Ciprofloxacin = 0.5 0.12 0.5 1
17 Clindamycin = 0.25 0.06 0.25 1
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17 Erythromycin = 1 0.25 1 1
17 Gentamicin <= 1 0.12 1 1
17 Linezolid = 4 1 4 1
17 Sulfamethoxazole <= 64 32 128 1
17 Tetracycline = 1 0.12 1 1
17 Trimethoprim = 4 1 4 1
17 Vancomycin <= 1 0.5 2 1
19 Cefoxitin = 2 1 4 1
19 Chloramphenicol = 8 2 16 1
19 Ciprofloxacin <= 0.25 0.12 0.5 1
19 Clindamycin <= 0.12 0.06 0.25 1
19 Erythromycin = 0.5 0.25 1 1
19 Gentamicin <= 1 0.12 1 1
19 Linezolid = 2 1 4 1
19 Sulfamethoxazole <= 64 32 128 1
19 Tetracycline <= 0.5 0.12 1 1
19 Trimethoprim <= 2 1 4 1
19 Vancomycin <= 1 0.5 2 1
20 Cefoxitin = 4 1 4 1
20 Chloramphenicol = 16 2 16 1
20 Ciprofloxacin = 0.5 0.12 0.5 1
20 Clindamycin <= 0.12 0.06 0.25 1
20 Erythromycin = 0.5 0.25 1 1
20 Gentamicin <= 1 0.12 1 1
20 Linezolid = 4 1 4 1
20 Sulfamethoxazole <= 64 32 128 1
20 Tetracycline <= 0.5 0.12 1 1
20 Trimethoprim = 4 1 4 1
20 Vancomycin <= 1 0.5 2 1
22 Cefoxitin = 4 1 4 1
22 Chloramphenicol = 8 2 16 1
22 Ciprofloxacin <= 0.25 0.12 0.5 1
22 Clindamycin <= 0.12 0.06 0.25 1
22 Erythromycin <= 0.25 0.25 1 1
22 Gentamicin <= 1 0.12 1 1
22 Linezolid = 2 1 4 1
22 Sulfamethoxazole <= 64 32 128 1
22 Tetracycline <= 0.5 0.12 1 1
22 Trimethoprim <= 2 1 4 1
22 Vancomycin <= 1 0.5 2 1
23 Cefoxitin = 4 1 4 1
23 Chloramphenicol = 8 2 16 1
23 Ciprofloxacin <= 0.25 0.12 0.5 1
23 Clindamycin <= 0.12 0.06 0.25 1
23 Erythromycin = 0.5 0.25 1 1
23 Gentamicin <= 1 0.12 1 1
23 Linezolid = 2 1 4 1
23 Sulfamethoxazole <= 64 32 128 1
23 Tetracycline <= 0.5 0.12 1 1
23 Trimethoprim <= 2 1 4 1
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23 Vancomycin <= 1 0.5 2 1
25 Clindamycin = 0.12 0.06 0.25 1
25 Erythromycin = 0.5 0.25 1 1
25 Sulfamethoxazole‐Trimethoprim <= 0.12 0 0.5 1
25 Tetracycline = 0.5 0.12 1 1
26 Cefoxitin = 4 1 4 1
26 Chloramphenicol = 8 2 16 1
26 Ciprofloxacin = 0.5 0.12 0.5 1
26 Clindamycin <= 0.12 0.06 0.25 1
26 Erythromycin = 0.5 0.25 1 1
26 Gentamicin <= 1 0.12 1 1
26 Linezolid = 4 1 4 1
26 Sulfamethoxazole <= 64 32 128 1
26 Sulfamethoxazole‐Trimethoprim = 0.5 0 0.5 1
26 Tetracycline <= 0.5 0.12 1 1
26 Trimethoprim <= 2 1 4 1
26 Vancomycin <= 1 0.5 2 1
29 Cefoxitin ‐ 4 1 4 1
29 Chloramphenicol ‐ 4 2 16 1
29 Ciprofloxacin ‐ 0.5 0.12 0.5 1
29 Clindamycin ‐ 0.25 0.06 0.25 1
29 Erythromycin ‐ 0.5 0.25 1 1
29 Gentamicin ‐ 0.5 0.12 1 1
29 Linezolid ‐ 1 1 4 1
29 Sulfamethoxazole ‐ 64 32 128 1
29 Tetracycline ‐ 0.25 0.12 1 1
29 Trimethoprim ‐ 2 1 4 1
29 Vancomycin ‐ 0.5 0.5 2 1
30 Cefoxitin = 4 1 4 1
30 Chloramphenicol <= 4 2 16 1
30 Ciprofloxacin <= 0.25 0.12 0.5 1
30 Clindamycin <= 0.12 0.06 0.25 1
30 Erythromycin <= 0.25 0.25 1 1
30 Gentamicin <= 1 0.12 1 1
30 Linezolid = 2 1 4 1
30 Sulfamethoxazole <= 64 32 128 1
30 Tetracycline <= 0.5 0.12 1 1
30 Trimethoprim <= 2 1 4 1
30 Vancomycin <= 1 0.5 2 1
33 Cefoxitin = 2 1 4 1
33 Chloramphenicol = 8 2 16 1
33 Ciprofloxacin = 0.25 0.12 0.5 1
33 Clindamycin <= 0.25 0.06 0.25 1
33 Erythromycin = 0.5 0.25 1 1
33 Gentamicin <= 0.5 0.12 1 1
33 Tetracycline <= 0.5 0.12 1 1
33 Trimethoprim = 2 1 4 1
34 Cefoxitin = 4 1 4 1
34 Chloramphenicol <= 4 2 16 1
34 Ciprofloxacin <= 0.25 0.12 0.5 1
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34 Clindamycin <= 0.12 0.06 0.25 1
34 Erythromycin = 0.5 0.25 1 1
34 Gentamicin <= 1 0.12 1 1
34 Linezolid <= 1 1 4 1
34 Sulfamethoxazole <= 64 32 128 1
34 Tetracycline <= 0.5 0.12 1 1
34 Trimethoprim <= 2 1 4 1
34 Vancomycin <= 1 0.5 2 1
36 Cefoxitin ‐ 4 1 4 1
36 Chloramphenicol ‐ 8 2 16 1
36 Ciprofloxacin <= 0.25 0.12 0.5 1
36 Clindamycin <= 0.12 0.06 0.25 1
36 Erythromycin ‐ 0.5 0.25 1 1
36 Gentamicin <= 1 0.12 1 1
36 Linezolid ‐ 2 1 4 1
36 Sulfamethoxazole <= 64 32 128 1
36 Tetracycline <= 0.5 0.12 1 1
36 Trimethoprim <= 2 1 4 1
36 Vancomycin <= 1 0.5 2 1
37 Cefoxitin = 4 1 4 1
37 Chloramphenicol = 8 2 16 1
37 Ciprofloxacin = 0.25 0.12 0.5 1
37 Erythromycin = 0.25 0.25 1 1
37 Gentamicin = 0.25 0.12 1 1
37 Linezolid = 2 1 4 1
37 Sulfamethoxazole = 32 32 128 1
37 Tetracycline = 1 0.12 1 1
37 Trimethoprim = 1 1 4 1
37 Vancomycin <= 1 0.5 2 1
39 Cefoxitin ‐ 2 1 4 1
39 Chloramphenicol ‐ 8 2 16 1
39 Ciprofloxacin ‐ 0.5 0.12 0.5 1
39 Clindamycin ‐ 0.25 0.06 0.25 1
39 Erythromycin ‐ 1 0.25 1 1
39 Gentamicin <= 1 0.12 1 1
39 Linezolid ‐ 2 1 4 1
39 Sulfamethoxazole <= 64 32 128 1
39 Tetracycline <= 0.5 0.12 1 1
39 Trimethoprim ‐ 2 1 4 1
39 Vancomycin <= 1 0.5 2 1
40 Cefoxitin = 1 1 4 1
40 Chloramphenicol = 8 2 16 1
40 Ciprofloxacin = 0.25 0.12 0.5 1
40 Clindamycin = 0.25 0.06 0.25 1
40 Erythromycin = 0.5 0.25 1 1
40 Gentamicin = 1 0.12 1 1
40 Linezolid = 2 1 4 1
40 Sulfamethoxazole = 64 32 128 1
40 Tetracycline = 1 0.12 1 1
40 Trimethoprim = 1 1 4 1
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40 Vancomycin = 1 0.5 2 1
41 Cefoxitin = 1 1 4 1
41 Chloramphenicol = 8 2 16 1
41 Ciprofloxacin <= 0.25 0.12 0.5 1
41 Clindamycin = 0.25 0.06 0.25 1
41 Erythromycin = 0.5 0.25 1 1
41 Gentamicin <= 1 0.12 1 1
41 Linezolid = 2 1 4 1
41 Sulfamethoxazole <= 64 32 128 1
41 Tetracycline <= 0.5 0.12 1 1
41 Trimethoprim <= 2 1 4 1
41 Vancomycin <= 1 0.5 2 1
42 Cefoxitin = 4 1 4 1
42 Chloramphenicol = 8 2 16 1
42 Ciprofloxacin <= 0.25 0.12 0.5 1
42 Clindamycin <= 0.12 0.06 0.25 1
42 Erythromycin = 0.5 0.25 1 1
42 Gentamicin <= 1 0.12 1 1
42 Linezolid = 2 1 4 1
42 Sulfamethoxazole <= 64 32 128 1
42 Tetracycline <= 0.5 0.12 1 1
42 Trimethoprim <= 2 1 4 1
42 Vancomycin <= 1 0.5 2 1
45 Cefoxitin = 4 1 4 1
45 Chloramphenicol = 8 2 16 1
45 Ciprofloxacin = 0.5 0.12 0.5 1
45 Clindamycin <= 0.12 0.06 0.25 1
45 Erythromycin = 0.5 0.25 1 1
45 Gentamicin <= 1 0.12 1 1
45 Linezolid = 2 1 4 1
45 Sulfamethoxazole = 128 32 128 1
45 Tetracycline = 1 0.12 1 1
45 Trimethoprim <= 2 1 4 1
45 Vancomycin <= 1 0.5 2 1
56 Cefoxitin = 1 1 4 1
56 Chloramphenicol = 8 2 16 1
56 Ciprofloxacin <= 0.25 0.12 0.5 1
56 Clindamycin <= 0.12 0.06 0.25 1
56 Erythromycin = 0.5 0.25 1 1
56 Gentamicin <= 1 0.12 1 1
56 Linezolid = 2 1 4 1
56 Sulfamethoxazole <= 64 32 128 1
56 Tetracycline <= 0.5 0.12 1 1
56 Trimethoprim <= 2 1 4 1
56 Vancomycin <= 1 0.5 2 1
59 Cefoxitin = 4 1 4 1
59 Chloramphenicol = 8 2 16 1
59 Ciprofloxacin <= 0.25 0.12 0.5 1
59 Clindamycin <= 0.12 0.06 0.25 1
59 Erythromycin = 0.5 0.25 1 1
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59 Gentamicin <= 1 0.12 1 1
59 Linezolid = 2 1 4 1
59 Sulfamethoxazole <= 64 32 128 1
59 Tetracycline <= 0.5 0.12 1 1
59 Trimethoprim <= 2 1 4 1
59 Vancomycin <= 1 0.5 2 1
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Escherichia coli  ATCC 25922 results
Lab. Code Panel Antimicrobial Operator Read_value Min Value Max Value Score
2 1 Ampicillin = 4 2.0 8.0 1
2 1 Cefotaxime <= 0.25 0.03 0.12 1
2 1 Ceftazidime <= 0.5 0.06 0.5 1
2 1 Chloramphenicol <= 8 2.0 8.0 1
2 1 Ciprofloxacin <= 0.015 0.004 0.015 1
2 1 Colistin <= 1 0.25 2.0 1
2 1 Gentamicin <= 0.5 0.25 1.0 1
2 1 Meropenem <= 0.03 0.008 0.06 1
2 1 Nalidixic acid <= 4 1.0 4.0 1
2 1 Sulfamethoxazole = 32 8.0 32.0 1
2 1 Tetracycline <= 2 0.5 2.0 1
2 1 Tigecycline <= 0.25 0.03 0.25 1
2 1 Trimethoprim = 1 0.5 2.0 1
2 2 Cefepime <= 0.06 0.015 0.12 1
2 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
2 2 Cefoxitin = 4 2.0 8.0 1
2 2 Ceftazidime <= 0.25 0.06 0.5 1
2 2 Ertapenem <= 0.015 0.004 0.015 1
2 2 Imipenem <= 0.12 0.06 0.25 1
2 2 Meropenem <= 0.03 0.008 0.06 1
4 1 Ampicillin = 8 2.0 8.0 1
4 1 Cefotaxime <= 0.25 0.03 0.12 1
4 1 Ceftazidime <= 0.5 0.06 0.5 1
4 1 Chloramphenicol <= 8 2.0 8.0 1
4 1 Ciprofloxacin <= 0.015 0.004 0.015 1
4 1 Colistin <= 1 0.25 2.0 1
4 1 Gentamicin <= 0.5 0.25 1.0 1
4 1 Meropenem <= 0.03 0.008 0.06 1
4 1 Nalidixic acid <= 4 1.0 4.0 1
4 1 Sulfamethoxazole = 16 8.0 32.0 1
4 1 Tetracycline <= 2 0.5 2.0 1
4 1 Tigecycline <= 0.25 0.03 0.25 1
4 1 Trimethoprim = 0.5 0.5 2.0 1
4 2 Cefepime <= 0.06 0.015 0.12 1
4 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
4 2 Cefoxitin = 4 2.0 8.0 1
4 2 Ceftazidime <= 0.25 0.06 0.5 1
4 2 Ertapenem <= 0.015 0.004 0.015 1
4 2 Imipenem <= 0.12 0.06 0.25 1
4 2 Meropenem <= 0.03 0.008 0.06 1
6 1 Ampicillin = 4 2.0 8.0 1
6 1 Cefotaxime <= 0.25 0.03 0.12 1
6 1 Ceftazidime <= 0.5 0.06 0.5 1
6 1 Chloramphenicol <= 8 2.0 8.0 1
6 1 Ciprofloxacin <= 0.015 0.004 0.015 1
6 1 Colistin <= 1 0.25 2.0 1
6 1 Gentamicin <= 0.5 0.25 1.0 1
6 1 Meropenem <= 0.03 0.008 0.06 1
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6 1 Nalidixic acid <= 4 1.0 4.0 1
6 1 Sulfamethoxazole = 16 8.0 32.0 1
6 1 Tetracycline <= 2 0.5 2.0 1
6 1 Tigecycline <= 0.25 0.03 0.25 1
6 1 Trimethoprim <= 0.25 0.5 2.0 0
6 2 Cefepime <= 0.06 0.015 0.12 1
6 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
6 2 Cefoxitin = 2 2.0 8.0 1
6 2 Ceftazidime <= 0.25 0.06 0.5 1
6 2 Ertapenem <= 0.015 0.004 0.015 1
6 2 Imipenem = 0.25 0.06 0.25 1
6 2 Meropenem <= 0.03 0.008 0.06 1
9 1 Ampicillin = 4 2.0 8.0 1
9 1 Ceftazidime <= 0.5 0.06 0.5 1
9 1 Chloramphenicol <= 8 2.0 8.0 1
9 1 Ciprofloxacin <= 0.015 0.004 0.015 1
9 1 Colistin <= 1 0.25 2.0 1
9 1 Gentamicin <= 0.5 0.25 1.0 1
9 1 Meropenem <= 0.03 0.008 0.06 1
9 1 Nalidixic acid <= 4 1.0 4.0 1
9 1 Sulfamethoxazole = 16 8.0 32.0 1
9 1 Tetracycline <= 2 0.5 2.0 1
9 1 Tigecycline <= 0.25 0.03 0.25 1
9 1 Trimethoprim = 1 0.5 2.0 1
9 2 Cefepime = 0.06 0.015 0.12 1
9 2 Cefoxitin = 4 2.0 8.0 1
9 2 Ceftazidime <= 0.25 0.06 0.5 1
9 2 Ertapenem <= 0.015 0.004 0.015 1
9 2 Imipenem <= 0.12 0.06 0.25 1
9 2 Meropenem <= 0.03 0.008 0.06 1
11 1 Ampicillin = 4 2.0 8.0 1
11 1 Cefotaxime <= 0.25 0.03 0.12 1
11 1 Ceftazidime <= 0.5 0.06 0.5 1
11 1 Chloramphenicol <= 8 2.0 8.0 1
11 1 Ciprofloxacin <= 0.015 0.004 0.015 1
11 1 Colistin <= 1 0.25 2.0 1
11 1 Gentamicin = 1 0.25 1.0 1
11 1 Meropenem <= 0.03 0.008 0.06 1
11 1 Nalidixic acid <= 4 1.0 4.0 1
11 1 Sulfamethoxazole = 16 8.0 32.0 1
11 1 Tetracycline <= 2 0.5 2.0 1
11 1 Tigecycline <= 0.25 0.03 0.25 1
11 1 Trimethoprim = 0.25 0.5 2.0 0
11 2 Cefepime <= 0.06 0.015 0.12 1
11 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
11 2 Cefoxitin = 4 2.0 8.0 1
11 2 Ceftazidime <= 0.25 0.06 0.5 1
11 2 Ertapenem <= 0.015 0.004 0.015 1
11 2 Imipenem <= 0.12 0.06 0.25 1
11 2 Meropenem <= 0.03 0.008 0.06 1
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12 1 Ampicillin = 4 2.0 8.0 1
12 1 Cefotaxime <= 0.25 0.03 0.12 1
12 1 Ceftazidime <= 0.5 0.06 0.5 1
12 1 Chloramphenicol <= 8 2.0 8.0 1
12 1 Ciprofloxacin <= 0.015 0.004 0.015 1
12 1 Colistin <= 1 0.25 2.0 1
12 1 Gentamicin <= 0.5 0.25 1.0 1
12 1 Meropenem <= 0.03 0.008 0.06 1
12 1 Nalidixic acid <= 4 1.0 4.0 1
12 1 Sulfamethoxazole = 32 8.0 32.0 1
12 1 Tetracycline <= 2 0.5 2.0 1
12 1 Tigecycline <= 0.25 0.03 0.25 1
12 1 Trimethoprim = 0.5 0.5 2.0 1
12 2 Cefepime <= 0.06 0.015 0.12 1
12 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
12 2 Cefoxitin = 4 2.0 8.0 1
12 2 Ceftazidime <= 0.25 0.06 0.5 1
12 2 Ertapenem <= 0.015 0.004 0.015 1
12 2 Imipenem <= 0.12 0.06 0.25 1
12 2 Meropenem <= 0.03 0.008 0.06 1
16 1 Ampicillin = 4 2.0 8.0 1
16 1 Cefotaxime <= 0.25 0.03 0.12 1
16 1 Ceftazidime <= 0.5 0.06 0.5 1
16 1 Chloramphenicol <= 8 2.0 8.0 1
16 1 Ciprofloxacin <= 0.015 0.004 0.015 1
16 1 Colistin <= 1 0.25 2.0 1
16 1 Gentamicin <= 0.5 0.25 1.0 1
16 1 Meropenem <= 0.03 0.008 0.06 1
16 1 Nalidixic acid <= 4 1.0 4.0 1
16 1 Sulfamethoxazole = 32 8.0 32.0 1
16 1 Tetracycline <= 2 0.5 2.0 1
16 1 Tigecycline <= 0.25 0.03 0.25 1
16 1 Trimethoprim = 0.5 0.5 2.0 1
16 2 Cefepime <= 0.06 0.015 0.12 1
16 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
16 2 Cefoxitin = 4 2.0 8.0 1
16 2 Ceftazidime <= 0.25 0.06 0.5 1
16 2 Ertapenem <= 0.015 0.004 0.015 1
16 2 Imipenem <= 0.12 0.06 0.25 1
16 2 Meropenem <= 0.03 0.008 0.06 1
17 1 Ampicillin = 4 2.0 8.0 1
17 1 Cefotaxime <= 0.25 0.03 0.12 1
17 1 Ceftazidime <= 0.5 0.06 0.5 1
17 1 Chloramphenicol <= 8 2.0 8.0 1
17 1 Ciprofloxacin <= 0.15 0.004 0.015 1
17 1 Colistin <= 1 0.25 2.0 1
17 1 Gentamicin <= 0.5 0.25 1.0 1
17 1 Meropenem <= 0.03 0.008 0.06 1
17 1 Nalidixic acid <= 4 1.0 4.0 1
17 1 Sulfamethoxazole = 16 8.0 32.0 1
Appendix 6c
Appendices EURL-AR EQAS EC-ENT-ST 2016 Page 65 of 81
17 1 Tetracycline <= 2 0.5 2.0 1
17 1 Tigecycline <= 0.25 0.03 0.25 1
17 1 Trimethoprim = 0.5 0.5 2.0 1
17 2 Cefepime <= 0.06 0.015 0.12 1
17 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
17 2 Cefoxitin = 4 2.0 8.0 1
17 2 Ceftazidime <= 0.25 0.06 0.5 1
17 2 Ertapenem <= 0.015 0.004 0.015 1
17 2 Imipenem = 0.25 0.06 0.25 1
17 2 Meropenem <= 0.03 0.008 0.06 1
18 1 Ampicillin = 2 2.0 8.0 1
18 1 Cefotaxime <= 0.25 0.03 0.12 1
18 1 Ceftazidime <= 0.5 0.06 0.5 1
18 1 Chloramphenicol <= 8 2.0 8.0 1
18 1 Ciprofloxacin <= 0.015 0.004 0.015 1
18 1 Colistin <= 1 0.25 2.0 1
18 1 Gentamicin <= 0.5 0.25 1.0 1
18 1 Meropenem <= 0.03 0.008 0.06 1
18 1 Nalidixic acid <= 4 1.0 4.0 1
18 1 Sulfamethoxazole = 16 8.0 32.0 1
18 1 Tetracycline <= 2 0.5 2.0 1
18 1 Tigecycline <= 0.25 0.03 0.25 1
18 1 Trimethoprim = 1 0.5 2.0 1
18 2 Cefepime <= 0.06 0.015 0.12 1
18 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
18 2 Cefoxitin = 4 2.0 8.0 1
18 2 Ceftazidime <= 0.25 0.06 0.5 1
18 2 Ertapenem <= 0.015 0.004 0.015 1
18 2 Imipenem <= 0.12 0.06 0.25 1
18 2 Meropenem <= 0.03 0.008 0.06 1
19 1 Ampicillin = 4 2.0 8.0 1
19 1 Cefotaxime <= 0.25 0.03 0.12 1
19 1 Ceftazidime <= 0.5 0.06 0.5 1
19 1 Chloramphenicol <= 8 2.0 8.0 1
19 1 Ciprofloxacin <= 0.015 0.004 0.015 1
19 1 Colistin <= 1 0.25 2.0 1
19 1 Gentamicin <= 0.5 0.25 1.0 1
19 1 Meropenem <= 0.03 0.008 0.06 1
19 1 Nalidixic acid <= 4 1.0 4.0 1
19 1 Sulfamethoxazole = 32 8.0 32.0 1
19 1 Tetracycline <= 2 0.5 2.0 1
19 1 Tigecycline <= 0.25 0.03 0.25 1
19 1 Trimethoprim = 0.5 0.5 2.0 1
19 2 Cefepime <= 0.06 0.015 0.12 1
19 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
19 2 Cefoxitin = 4 2.0 8.0 1
19 2 Ceftazidime <= 0.25 0.06 0.5 1
19 2 Ertapenem <= 0.015 0.004 0.015 1
19 2 Imipenem <= 0.12 0.06 0.25 1
19 2 Meropenem <= 0.03 0.008 0.06 1
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20 1 Ampicillin = 4 2.0 8.0 1
20 1 Cefotaxime <= 0.25 0.03 0.12 1
20 1 Ceftazidime <= 0.5 0.06 0.5 1
20 1 Chloramphenicol <= 8 2.0 8.0 1
20 1 Ciprofloxacin <= 0.015 0.004 0.015 1
20 1 Colistin <= 1 0.25 2.0 1
20 1 Gentamicin <= 0.5 0.25 1.0 1
20 1 Meropenem <= 0.03 0.008 0.06 1
20 1 Nalidixic acid <= 4 1.0 4.0 1
20 1 Sulfamethoxazole = 16 8.0 32.0 1
20 1 Tetracycline <= 2 0.5 2.0 1
20 1 Tigecycline <= 0.25 0.03 0.25 1
20 1 Trimethoprim = 0.5 0.5 2.0 1
20 2 Cefepime <= 0.06 0.015 0.12 1
20 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
20 2 Cefoxitin = 4 2.0 8.0 1
20 2 Ceftazidime <= 0.25 0.06 0.5 1
20 2 Ertapenem <= 0.015 0.004 0.015 1
20 2 Imipenem <= 0.12 0.06 0.25 1
20 2 Meropenem <= 0.03 0.008 0.06 1
22 1 Ampicillin = 2 2.0 8.0 1
22 1 Cefotaxime <= 0.25 0.03 0.12 1
22 1 Ceftazidime <= 0.5 0.06 0.5 1
22 1 Chloramphenicol <= 8 2.0 8.0 1
22 1 Ciprofloxacin <= 0.03 0.004 0.015 1
22 1 Colistin <= 1 0.25 2.0 1
22 1 Gentamicin <= 0.5 0.25 1.0 1
22 1 Meropenem <= 0.03 0.008 0.06 1
22 1 Nalidixic acid <= 4 1.0 4.0 1
22 1 Sulfamethoxazole = 16 8.0 32.0 1
22 1 Tetracycline <= 2 0.5 2.0 1
22 1 Tigecycline <= 0.25 0.03 0.25 1
22 1 Trimethoprim = 0.5 0.5 2.0 1
22 2 Cefepime <= 0.06 0.015 0.12 1
22 2 Cefoxitin = 2 2.0 8.0 1
22 2 Ceftazidime <= 0.25 0.06 0.5 1
22 2 Ertapenem <= 0.015 0.004 0.015 1
22 2 Imipenem <= 0.12 0.06 0.25 1
22 2 Meropenem <= 0.03 0.008 0.06 1
23 1 Ampicillin = 2 2.0 8.0 1
23 1 Cefotaxime <= 0.25 0.03 0.12 1
23 1 Ceftazidime <= 0.5 0.06 0.5 1
23 1 Chloramphenicol <= 8 2.0 8.0 1
23 1 Ciprofloxacin <= 0.015 0.004 0.015 1
23 1 Colistin <= 1 0.25 2.0 1
23 1 Gentamicin <= 0.5 0.25 1.0 1
23 1 Meropenem <= 0.03 0.008 0.06 1
23 1 Nalidixic acid <= 4 1.0 4.0 1
23 1 Sulfamethoxazole = 16 8.0 32.0 1
23 1 Tetracycline <= 2 0.5 2.0 1
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23 1 Tigecycline <= 0.25 0.03 0.25 1
23 1 Trimethoprim = 0.5 0.5 2.0 1
23 2 Cefepime <= 0.06 0.015 0.12 1
23 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
23 2 Cefoxitin = 2 2.0 8.0 1
23 2 Ceftazidime <= 0.25 0.06 0.5 1
23 2 Ertapenem <= 0.015 0.004 0.015 1
23 2 Imipenem = 0.25 0.06 0.25 1
23 2 Meropenem <= 0.03 0.008 0.06 1
25 1 Ampicillin = 8 2.0 8.0 1
25 1 Cefotaxime <= 0.25 0.03 0.12 1
25 1 Ceftazidime <= 0.5 0.06 0.5 1
25 1 Chloramphenicol <= 8 2.0 8.0 1
25 1 Ciprofloxacin <= 0.015 0.004 0.015 1
25 1 Colistin <= 1 0.25 2.0 1
25 1 Gentamicin <= 0.5 0.25 1.0 1
25 1 Meropenem <= 0.03 0.008 0.06 1
25 1 Nalidixic acid <= 4 1.0 4.0 1
25 1 Sulfamethoxazole <= 8 8.0 32.0 1
25 1 Tetracycline <= 2 0.5 2.0 1
25 1 Tigecycline <= 0.25 0.03 0.25 1
25 1 Trimethoprim = 0.5 0.5 2.0 1
25 2 Cefepime <= 0.06 0.015 0.12 1
25 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
25 2 Cefoxitin = 4 2.0 8.0 1
25 2 Ceftazidime <= 0.25 0.06 0.5 1
25 2 Ertapenem <= 0.015 0.004 0.015 1
25 2 Imipenem <= 0.12 0.06 0.25 1
25 2 Meropenem <= 0.03 0.008 0.06 1
26 1 Ampicillin = 2 2.0 8.0 1
26 1 Cefotaxime <= 0.25 0.03 0.12 1
26 1 Ceftazidime <= 0.5 0.06 0.5 1
26 1 Chloramphenicol <= 8 2.0 8.0 1
26 1 Ciprofloxacin <= 0.015 0.004 0.015 1
26 1 Colistin <= 1 0.25 2.0 1
26 1 Gentamicin = 1 0.25 1.0 1
26 1 Meropenem <= 0.03 0.008 0.06 1
26 1 Nalidixic acid <= 4 1.0 4.0 1
26 1 Sulfamethoxazole <= 8 8.0 32.0 1
26 1 Tetracycline <= 8 0.5 2.0 1
26 1 Tigecycline <= 0.25 0.03 0.25 1
26 1 Trimethoprim = 0.5 0.5 2.0 1
29 1 Ampicillin = 4 2.0 8.0 1
29 1 Cefotaxime = 0.12 0.03 0.12 1
29 1 Ceftazidime = 0.25 0.06 0.5 1
29 1 Chloramphenicol = 8 2.0 8.0 1
29 1 Ciprofloxacin = 0.015 0.004 0.015 1
29 1 Colistin = 1 0.25 2.0 1
29 1 Gentamicin = 1 0.25 1.0 1
29 1 Meropenem = 0.06 0.008 0.06 1
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29 1 Nalidixic acid = 2 1.0 4.0 1
29 1 Sulfamethoxazole = 32 8.0 32.0 1
29 1 Tetracycline = 2 0.5 2.0 1
29 1 Tigecycline = 0.25 0.03 0.25 1
29 1 Trimethoprim = 1 0.5 2.0 1
29 2 Cefepime = 0.12 0.015 0.12 1
29 2 Cefoxitin = 4 2.0 8.0 1
29 2 Ceftazidime = 0.25 0.06 0.5 1
29 2 Ertapenem = 0.015 0.004 0.015 1
29 2 Imipenem = 0.25 0.06 0.25 1
29 2 Meropenem = 0.06 0.008 0.06 1
30 1 Ampicillin = 4 2.0 8.0 1
30 1 Cefotaxime <= 0.25 0.03 0.12 1
30 1 Ceftazidime <= 0.5 0.06 0.5 1
30 1 Chloramphenicol <= 8 2.0 8.0 1
30 1 Ciprofloxacin <= 0.015 0.004 0.015 1
30 1 Colistin <= 1 0.25 2.0 1
30 1 Gentamicin <= 0.5 0.25 1.0 1
30 1 Meropenem <= 0.03 0.008 0.06 1
30 1 Nalidixic acid <= 4 1.0 4.0 1
30 1 Sulfamethoxazole = 16 8.0 32.0 1
30 1 Tetracycline <= 2 0.5 2.0 1
30 1 Tigecycline <= 0.25 0.03 0.25 1
30 1 Trimethoprim = 0.5 0.5 2.0 1
30 2 Cefepime <= 0.06 0.015 0.12 1
30 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
30 2 Cefoxitin = 2 2.0 8.0 1
30 2 Ceftazidime <= 0.25 0.06 0.5 1
30 2 Ertapenem <= 0.015 0.004 0.015 1
30 2 Imipenem <= 0.12 0.06 0.25 1
30 2 Meropenem <= 0.03 0.008 0.06 1
33 1 Ampicillin = 2 2.0 8.0 1
33 1 Cefotaxime <= 0.25 0.03 0.12 1
33 1 Ceftazidime <= 0.5 0.06 0.5 1
33 1 Chloramphenicol <= 8 2.0 8.0 1
33 1 Ciprofloxacin <= 0.015 0.004 0.015 1
33 1 Colistin <= 1 0.25 2.0 1
33 1 Gentamicin <= 0.5 0.25 1.0 1
33 1 Meropenem <= 0.03 0.008 0.06 1
33 1 Nalidixic acid <= 4 1.0 4.0 1
33 1 Sulfamethoxazole = 32 8.0 32.0 1
33 1 Tetracycline <= 2 0.5 2.0 1
33 1 Tigecycline <= 0.25 0.03 0.25 1
33 1 Trimethoprim = 0.5 0.5 2.0 1
33 2 Cefepime <= 0.06 0.015 0.12 1
33 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
33 2 Cefoxitin = 4 2.0 8.0 1
33 2 Ceftazidime <= 0.25 0.06 0.5 1
33 2 Ertapenem <= 0.015 0.004 0.015 1
33 2 Imipenem = 0.25 0.06 0.25 1
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33 2 Meropenem <= 0.03 0.008 0.06 1
34 1 Ampicillin = 4 2.0 8.0 1
34 1 Cefotaxime <= 0.25 0.03 0.12 1
34 1 Ceftazidime <= 0.5 0.06 0.5 1
34 1 Chloramphenicol <= 8 2.0 8.0 1
34 1 Ciprofloxacin <= 0.015 0.004 0.015 1
34 1 Colistin <= 1 0.25 2.0 1
34 1 Gentamicin <= 0.5 0.25 1.0 1
34 1 Meropenem <= 0.03 0.008 0.06 1
34 1 Nalidixic acid <= 4 1.0 4.0 1
34 1 Sulfamethoxazole <= 8 8.0 32.0 1
34 1 Tetracycline <= 2 0.5 2.0 1
34 1 Tigecycline <= 0.25 0.03 0.25 1
34 1 Trimethoprim = 0.5 0.5 2.0 1
34 2 Cefepime <= 0.06 0.015 0.12 1
34 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
34 2 Cefoxitin = 2 2.0 8.0 1
34 2 Ceftazidime <= 0.25 0.06 0.5 1
34 2 Ertapenem <= 0.015 0.004 0.015 1
34 2 Imipenem <= 0.12 0.06 0.25 1
34 2 Meropenem <= 0.03 0.008 0.06 1
36 1 Ampicillin = 4 2.0 8.0 1
36 1 Cefotaxime <= 0.25 0.03 0.12 1
36 1 Ceftazidime <= 0.5 0.06 0.5 1
36 1 Chloramphenicol <= 8 2.0 8.0 1
36 1 Ciprofloxacin <= 0.015 0.004 0.015 1
36 1 Colistin <= 1 0.25 2.0 1
36 1 Gentamicin <= 0.5 0.25 1.0 1
36 1 Meropenem <= 0.03 0.008 0.06 1
36 1 Nalidixic acid <= 4 1.0 4.0 1
36 1 Sulfamethoxazole <= 8 8.0 32.0 1
36 1 Tetracycline <= 2 0.5 2.0 1
36 1 Tigecycline <= 0.25 0.03 0.25 1
36 1 Trimethoprim = 0.5 0.5 2.0 1
36 2 Cefepime <= 0.06 0.015 0.12 1
36 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
36 2 Cefoxitin = 4 2.0 8.0 1
36 2 Ceftazidime <= 0.25 0.06 0.5 1
36 2 Ertapenem <= 0.015 0.004 0.015 1
36 2 Imipenem <= 0.12 0.06 0.25 1
36 2 Meropenem <= 0.03 0.008 0.06 1
37 1 Ampicillin = 2 2.0 8.0 1
37 1 Cefotaxime <= 0.25 0.03 0.12 1
37 1 Ceftazidime <= 0.5 0.06 0.5 1
37 1 Chloramphenicol <= 8 2.0 8.0 1
37 1 Ciprofloxacin <= 0.015 0.004 0.015 1
37 1 Colistin <= 1 0.25 2.0 1
37 1 Gentamicin <= 0.5 0.25 1.0 1
37 1 Meropenem <= 0.03 0.008 0.06 1
37 1 Nalidixic acid <= 4 1.0 4.0 1
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37 1 Sulfamethoxazole <= 8 8.0 32.0 1
37 1 Tetracycline <= 2 0.5 2.0 1
37 1 Tigecycline <= 0.25 0.03 0.25 1
37 1 Trimethoprim = 0.5 0.5 2.0 1
37 2 Cefepime <= 0.06 0.015 0.12 1
37 2 Cefotaxime/clavulanic acid <= 0.25 0.03 0.12 1
37 2 Cefoxitin = 4 2.0 8.0 1
37 2 Ceftazidime <= 0.5 0.06 0.5 1
37 2 Ertapenem <= 0.015 0.004 0.015 1
37 2 Imipenem <= 0.125 0.06 0.25 1
37 2 Meropenem <= 0.03 0.008 0.06 1
38 1 Ampicillin = 8 2.0 8.0 1
38 1 Cefotaxime <= 0.25 0.03 0.12 1
38 1 Ceftazidime <= 0.5 0.06 0.5 1
38 1 Chloramphenicol <= 8 2.0 8.0 1
38 1 Ciprofloxacin <= 0.015 0.004 0.015 1
38 1 Colistin <= 1 0.25 2.0 1
38 1 Gentamicin <= 0.5 0.25 1.0 1
38 1 Meropenem <= 0.03 0.008 0.06 1
38 1 Nalidixic acid <= 4 1.0 4.0 1
38 1 Sulfamethoxazole = 16 8.0 32.0 1
38 1 Tetracycline <= 2 0.5 2.0 1
38 1 Tigecycline <= 0.25 0.03 0.25 1
38 1 Trimethoprim = 1 0.5 2.0 1
38 2 Cefepime <= 0.06 0.015 0.12 1
38 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
38 2 Cefoxitin = 4 2.0 8.0 1
38 2 Ceftazidime <= 0.25 0.06 0.5 1
38 2 Ertapenem <= 0.015 0.004 0.015 1
38 2 Imipenem <= 0.12 0.06 0.25 1
38 2 Meropenem <= 0.03 0.008 0.06 1
39 1 Ampicillin = 4 2.0 8.0 1
39 1 Cefotaxime <= 0.25 0.03 0.12 1
39 1 Ceftazidime <= 0.5 0.06 0.5 1
39 1 Chloramphenicol <= 8 2.0 8.0 1
39 1 Ciprofloxacin <= 0.015 0.004 0.015 1
39 1 Colistin <= 1 0.25 2.0 1
39 1 Gentamicin <= 0.5 0.25 1.0 1
39 1 Meropenem <= 0.03 0.008 0.06 1
39 1 Nalidixic acid <= 4 1.0 4.0 1
39 1 Sulfamethoxazole = 32 8.0 32.0 1
39 1 Tetracycline <= 2 0.5 2.0 1
39 1 Tigecycline <= 0.25 0.03 0.25 1
39 1 Trimethoprim = 0.5 0.5 2.0 1
39 2 Cefepime <= 0.06 0.015 0.12 1
39 2 Cefotaxime/clavulanic acid = 0.06 0.03 0.12 1
39 2 Cefoxitin = 2 2.0 8.0 1
39 2 Ceftazidime <= 0.25 0.06 0.5 1
39 2 Ertapenem <= 0.15 0.004 0.015 1
39 2 Imipenem = 0.25 0.06 0.25 1
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39 2 Meropenem <= 0.03 0.008 0.06 1
40 1 Ampicillin = 4 2.0 8.0 1
40 1 Cefotaxime = 0.12 0.03 0.12 1
40 1 Ceftazidime = 0.5 0.06 0.5 1
40 1 Chloramphenicol = 8 2.0 8.0 1
40 1 Ciprofloxacin = 0.015 0.004 0.015 1
40 1 Colistin = 2 0.25 2.0 1
40 1 Gentamicin = 0.5 0.25 1.0 1
40 1 Meropenem = 0.06 0.008 0.06 1
40 1 Nalidixic acid = 4 1.0 4.0 1
40 1 Sulfamethoxazole = 16 8.0 32.0 1
40 1 Tetracycline = 2 0.5 2.0 1
40 1 Tigecycline = 0.25 0.03 0.25 1
40 1 Trimethoprim = 0.5 0.5 2.0 1
40 2 Cefepime = 0.12 0.015 0.12 1
40 2 Cefotaxime/clavulanic acid = 0.06 0.03 0.12 1
40 2 Cefoxitin = 4 2.0 8.0 1
40 2 Ceftazidime = 0.5 0.06 0.5 1
40 2 Ertapenem = 0.015 0.004 0.015 1
40 2 Imipenem = 0.25 0.06 0.25 1
40 2 Meropenem = 0.06 0.008 0.06 1
41 1 Ampicillin = 4 2.0 8.0 1
41 1 Cefotaxime <= 0.25 0.03 0.12 1
41 1 Ceftazidime <= 0.5 0.06 0.5 1
41 1 Chloramphenicol <= 8 2.0 8.0 1
41 1 Ciprofloxacin <= 0.015 0.004 0.015 1
41 1 Colistin <= 1 0.25 2.0 1
41 1 Gentamicin = 1 0.25 1.0 1
41 1 Meropenem <= 0.03 0.008 0.06 1
41 1 Nalidixic acid <= 4 1.0 4.0 1
41 1 Sulfamethoxazole = 16 8.0 32.0 1
41 1 Tetracycline <= 2 0.5 2.0 1
41 1 Tigecycline <= 0.25 0.03 0.25 1
41 1 Trimethoprim = 1 0.5 2.0 1
41 2 Cefepime <= 0.06 0.015 0.12 1
41 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
41 2 Cefoxitin = 2 2.0 8.0 1
41 2 Ceftazidime <= 0.5 0.06 0.5 1
41 2 Ertapenem <= 0.015 0.004 0.015 1
41 2 Imipenem <= 0.12 0.06 0.25 1
41 2 Meropenem <= 0.03 0.008 0.06 1
42 1 Ampicillin = 8 2.0 8.0 1
42 1 Cefotaxime <= 0.25 0.03 0.12 1
42 1 Ceftazidime <= 0.5 0.06 0.5 1
42 1 Chloramphenicol <= 8 2.0 8.0 1
42 1 Ciprofloxacin <= 0.015 0.004 0.015 1
42 1 Colistin <= 1 0.25 2.0 1
42 1 Gentamicin <= 0.5 0.25 1.0 1
42 1 Meropenem <= 0.03 0.008 0.06 1
42 1 Nalidixic acid <= 4 1.0 4.0 1
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42 1 Sulfamethoxazole = 64 8.0 32.0 0
42 1 Tetracycline <= 2 0.5 2.0 1
42 1 Tigecycline <= 0.25 0.03 0.25 1
42 1 Trimethoprim = 2 0.5 2.0 1
42 2 Cefepime <= 0.06 0.015 0.12 1
42 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
42 2 Cefoxitin = 4 2.0 8.0 1
42 2 Ceftazidime <= 0.25 0.06 0.5 1
42 2 Ertapenem <= 0.015 0.004 0.015 1
42 2 Imipenem <= 0.12 0.06 0.25 1
42 2 Meropenem <= 0.03 0.008 0.06 1
45 1 Ampicillin = 4 2.0 8.0 1
45 1 Cefotaxime <= 0.25 0.03 0.12 1
45 1 Ceftazidime <= 0.5 0.06 0.5 1
45 1 Chloramphenicol <= 8 2.0 8.0 1
45 1 Ciprofloxacin <= 0.016 0.004 0.015 1
45 1 Colistin <= 1 0.25 2.0 1
45 1 Gentamicin <= 0.5 0.25 1.0 1
45 1 Meropenem <= 0.03 0.008 0.06 1
45 1 Nalidixic acid <= 4 1.0 4.0 1
45 1 Sulfamethoxazole = 32 8.0 32.0 1
45 1 Tetracycline <= 2 0.5 2.0 1
45 1 Tigecycline <= 0.25 0.03 0.25 1
45 1 Trimethoprim = 1 0.5 2.0 1
45 2 Cefepime <= 0.06 0.015 0.12 1
45 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
45 2 Cefoxitin = 4 2.0 8.0 1
45 2 Ceftazidime <= 0.25 0.06 0.5 1
45 2 Ertapenem <= 0.016 0.004 0.015 1
45 2 Imipenem <= 0.12 0.06 0.25 1
45 2 Meropenem <= 0.03 0.008 0.06 1
56 1 Ampicillin = 4 2.0 8.0 1
56 1 Cefotaxime <= 0.25 0.03 0.12 1
56 1 Ceftazidime <= 0.5 0.06 0.5 1
56 1 Chloramphenicol <= 8 2.0 8.0 1
56 1 Ciprofloxacin <= 0.015 0.004 0.015 1
56 1 Colistin <= 1 0.25 2.0 1
56 1 Gentamicin <= 0.5 0.25 1.0 1
56 1 Meropenem <= 0.03 0.008 0.06 1
56 1 Nalidixic acid <= 4 1.0 4.0 1
56 1 Sulfamethoxazole = 16 8.0 32.0 1
56 1 Tetracycline <= 2 0.5 2.0 1
56 1 Tigecycline <= 0.25 0.03 0.25 1
56 1 Trimethoprim = 1 0.5 2.0 1
56 2 Cefepime <= 0.06 0.015 0.12 1
56 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
56 2 Cefoxitin = 8 2.0 8.0 1
56 2 Ceftazidime <= 0.25 0.06 0.5 1
56 2 Ertapenem <= 0.015 0.004 0.015 1
56 2 Imipenem <= 0.12 0.06 0.25 1
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56 2 Meropenem <= 0.03 0.008 0.06 1
59 1 Ampicillin = 4 2.0 8.0 1
59 1 Cefotaxime <= 0.25 0.03 0.12 1
59 1 Ceftazidime <= 0.5 0.06 0.5 1
59 1 Chloramphenicol <= 8 2.0 8.0 1
59 1 Ciprofloxacin <= 0.015 0.004 0.015 1
59 1 Colistin <= 1 0.25 2.0 1
59 1 Gentamicin <= 0.5 0.25 1.0 1
59 1 Meropenem <= 0.03 0.008 0.06 1
59 1 Nalidixic acid <= 4 1.0 4.0 1
59 1 Sulfamethoxazole = 32 8.0 32.0 1
59 1 Tetracycline <= 2 0.5 2.0 1
59 1 Tigecycline <= 0.25 0.03 0.25 1
59 1 Trimethoprim = 0.5 0.5 2.0 1
59 2 Cefepime <= 0.06 0.015 0.12 1
59 2 Cefotaxime/clavulanic acid <= 0.06 0.03 0.12 1
59 2 Cefoxitin = 2 2.0 8.0 1
59 2 Ceftazidime <= 0.25 0.06 0.5 1
59 2 Ertapenem <= 0.015 0.004 0.015 1
59 2 Imipenem <= 0.12 0.06 0.25 1
59 2 Meropenem <= 0.03 0.008 0.06 1
60 1 Ampicillin = 4 2.0 8.0 1
60 1 Cefotaxime <= 0.25 0.03 0.12 1
60 1 Ceftazidime <= 0.5 0.06 0.5 1
60 1 Chloramphenicol <= 8 2.0 8.0 1
60 1 Ciprofloxacin <= 0.015 0.004 0.015 1
60 1 Colistin <= 1 0.25 2.0 1
60 1 Gentamicin <= 0.5 0.25 1.0 1
60 1 Meropenem <= 0.03 0.008 0.06 1
60 1 Nalidixic acid <= 4 1.0 4.0 1
60 1 Sulfamethoxazole <= 8 8.0 32.0 1
60 1 Tetracycline <= 2 0.5 2.0 1
60 1 Tigecycline <= 0.25 0.03 0.25 1
60 1 Trimethoprim <= 0.25 0.5 2.0 0
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Enterococci ‐ summary of results
EURL ENT‐10.1 EURL ENT‐10.2 EURL ENT‐10.3 EURL ENT‐10.4 EURL ENT‐10.5 EURL ENT‐10.6 EURL ENT‐10.7 EURL ENT‐10.8
Tested Correct Tested Correct Tested Correct Tested Correct Tested Correct Tested Correct Tested Correct Tested Correct
Ampicillin AMP 27 27 27 27 27 27 27 27 27 24 27 27 26 26 26 21
Chloramphenicol CHL 28 28 28 28 28 28 28 28 28 27 28 28 26 10 27 27
Ciprofloxacin CIP 27 27 27 27 27 27 27 27 27 27 27 26 26 26 26 26
Daptomycin DAP 25 25 25 25 25 25 25 25 25 25 25 25 24 24 24 24
Erythromycin ERY 28 28 28 27 28 28 28 28 28 27 28 28 27 27 27 26
Gentamicin GEN 28 28 28 27 28 28 28 27 28 28 28 26 27 26 27 27
Linezolid LZD 27 27 27 27 27 27 27 27 27 27 27 27 25 24 26 26
Quinopristin‐dalfopristin (Synercid) SYN 22 22 22 22 24 23 22 22 24 22 23 22 21 21 22 21
Teicoplanin TEI 25 25 25 25 25 25 25 25 25 25 25 25 24 23 24 24
Tetracycline TET 28 28 28 27 28 28 28 28 28 28 28 28 27 27 27 27
Tigecycline TGC 27 27 27 27 27 27 27 25 27 27 27 25 26 26 26 26
Vancomycin VAN 27 27 27 27 28 28 28 28 28 28 28 28 27 26 26 26

































Ampicillin AMP 0 0 0 0 0 0 0 0 3 11,1 0 0 0 0 5 19,2
Chloramphenicol CHL 0 0 0 0 0 0 0 0 1 3,6 0 0 16 61,5 0 0
Ciprofloxacin CIP 0 0 0 0 0 0 0 0 0 0 1 3,7 0 0 0 0
Daptomycin DAP 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Erythromycin ERY 0 0 1 3,6 0 0 0 0 1 3,6 0 0 0 0 1 3,7
Gentamicin GEN 0 0 1 3,6 0 0 1 3,6 0 0 2 7,1 1 3,7 0 0
Linezolid LZD 0 0 0 0 0 0 0 0 0 0 0 0 1 4 0 0
Quinopristin‐dalfopristin (Synercid) SYN 0 0 0 0 1 4,1 0 0 2 8,3 1 4,3 0 0 1 4,5
Teicoplanin TEI 0 0 0 0 0 0 0 0 0 0 0 0 1 4,1 0 0
Tetracycline TET 0 0 1 3,6 0 0 0 0 0 0 0 0 0 0 0 0
Tigecycline TGC 0 0 0 0 0 0 2 7,4 0 0 2 7,4 0 0 0 0
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Staphylococci ‐ summary of results 0
EURL ST‐10.1 EURL ST‐10.2 EURL ST‐10.3 EURL ST‐10.4 EURL ST‐10.5 EURL ST‐10.6 EURL ST‐10.7 EURL ST‐10.8
Tested Correct Tested Correct Tested Correct Tested Correct Tested Correct Tested Correct Tested Correct Tested Correct
Cefoxitin FOX 26 26 26 26 26 26 26 26 26 26 26 25 26 26 26 25
Chloramphenicol CHL 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26
Ciprofloxacin CIP 26 26 26 26 26 26 25 14 26 26 26 25 26 26 25 15
Clindamycin CLN 26 26 26 25 25 25 25 25 26 26 26 24 25 25 25 24
Erythromycin ERY 27 27 27 26 27 27 27 27 27 27 27 25 27 27 27 26
Gentamicin GEN 26 26 26 26 26 26 26 25 26 26 26 25 26 26 26 25
Linezolid LZD 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24
Mupirocin MUP 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24
Quinopristin‐dalfopristin (Synercid) SYN 23 23 23 22 23 23 23 23 23 21 22 18 23 23 23 22
Sulfamethoxazole SMX 25 25 25 25 25 25 25 24 25 23 25 25 25 23 25 25
Sulfamethoxazole‐Trimethoprim SXT 4 4 4 4 5 5 4 4 4 2 4 3 4 4 4 0
Tetracycline TET 27 27 27 27 27 26 27 27 27 27 27 27 27 26 27 27
Tiamulin TIA 23 23 23 22 23 23 23 23 23 23 22 18 23 23 23 22
Trimethoprim TMP 26 26 26 26 26 26 26 25 26 26 26 25 26 25 26 26
Vancomycin VAN 24 24 24 24 24 24 24 23 24 24 24 24 24 24 24 24


















Cefoxitin FOX 0 0 0 0 0 0 0 0 0 0 1 3,8 0 0 1 3,8
Chloramphenicol CHL 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Ciprofloxacin CIP 0 0 0 0 0 0 11 44 0 0 1 3,8 0 0 10 40
Clindamycin CLN 0 0 1 3,8 0 0 0 0 0 0 2 7,7 0 0 1 4
Erythromycin ERY 0 0 1 3,7 0 0 0 0 0 0 2 7,4 0 0 1 3,7
Gentamicin GEN 0 0 0 0 0 0 1 3,8 0 0 1 3,8 0 0 1 3,8
Linezolid LZD 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Mupirocin MUP 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Quinopristin‐dalfopristin (Synercid) SYN 0 0 1 4,3 0 0 0 0 2 8,7 4 18,2 0 0 1 4,3
Sulfamethoxazole SMX 0 0 0 0 0 0 1 4 2 8 0 0 2 8 0 0
Sulfamethoxazole‐Trimethoprim SXT 0 0 0 0 0 0 0 0 2 50 1 25 0 0 4 100
Tetracycline TET 0 0 0 0 1 3,7 0 0 0 0 0 0 1 3,7 0 0
Tiamulin TIA 0 0 1 4,3 0 0 0 0 0 0 4 18,2 0 0 1 4,3
Trimethoprim TMP 0 0 0 0 0 0 1 3,8 0 0 1 3,8 1 3,8 0 0
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Escherichia coli  - summary of results
EURL EC-10.1 EURL EC-10.2 EURL EC-10.3 EURL EC-10.4 EURL EC-10.5 EURL EC-10.6 EURL EC-10.7 EURL EC-10.8
Tested Correct Tested Correct Tested Correct Tested Correct Tested Correct Tested Correct Tested Correct Tested Correct
Ampicillin AMP 31 31 31 31 31 31 31 31 31 31 31 31 31 31 31 31
Azithromycin AZI 31 30 31 31 31 31 31 31 31 31 31 31 31 31 31 31
Cefepime FEP 31 29 31 31 31 28 31 29 31 31 − − − − 31 30
Cefotaxime FOT 62 62 62 62 62 62 62 62 62 62 31 30 31 31 62 62
Cefoxitin FOX 31 31 31 31 30 29 31 30 31 31 − − − − 31 31
Ceftazidime TAZ 62 62 62 61 62 62 62 62 62 62 31 31 31 31 62 62
Chloramphenicol CHL 31 31 31 31 30 29 30 29 31 31 31 31 31 31 31 31
Ciprofloxacin CIP 31 31 31 31 31 31 31 31 31 31 31 31 31 31 31 30
Colistin COL 31 30 31 31 31 28 31 31 31 31 31 31 31 31 31 31
Ertapenem ETP 31 30 31 31 31 31 31 31 31 30 − − − − 29 12
Gentamicin GEN 31 31 31 31 31 31 31 31 31 31 31 31 31 31 31 31
Imipenem IMI 31 31 31 31 31 31 31 31 31 31 − − − − 31 31
Meropenem MERO 62 62 62 62 62 62 62 62 62 62 31 31 31 31 62 62
Nalidixic acid NAL 31 31 31 31 31 31 31 31 31 31 31 31 31 31 31 31
Sulfamethoxazole SMX 31 31 31 31 31 31 31 31 31 29 31 31 31 31 31 27
Tetracycline TET 31 31 31 30 31 30 31 31 31 31 31 31 31 31 31 30
Tigecycline TGC 31 30 31 31 31 31 31 31 31 31 31 31 31 31 31 31
Trimethoprim TMP 31 31 31 31 31 31 31 31 31 31 31 28 31 31 31 30

































Ampicillin AMP 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Azithromycin AZI 1 3,2 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Cefepime FEP 2 6,5 0 0 3 9,7 2 6,5 0 0 − − − − 1 3,2
Cefotaxime FOT 0 0 0 0 0 0 0 0 0 0 1 3,2 0 0 0 0
Cefoxitin FOX 0 0 0 0 1 3,3 1 3,2 0 0 − − − − 0 0
Ceftazidime TAZ 0 0 1 1,6 0 0 0 0 0 0 0 0 0 0 0 0
Chloramphenicol CHL 0 0 0 0 1 3,3 1 3,3 0 0 0 0 0 0 0 0
Ciprofloxacin CIP 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 3,2
Colistin COL 1 3,2 0 0 3 9,7 0 0 0 0 0 0 0 0 0 0
Ertapenem ETP 1 3,2 0 0 0 0 0 0 1 3,2 − − − − 17 58,6
Gentamicin GEN 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Imipenem IMI 0 0 0 0 0 0 0 0 0 0 − − − − 0 0
Meropenem MERO 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Nalidixic acid NAL 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Sulfamethoxazole SMX 0 0 0 0 0 0 0 0 2 6,5 0 0 0 0 4 12,9
Tetracycline TET 0 0 1 3,2 1 3,2 0 0 0 0 0 0 0 0 1 3,2
Tigecycline TGC 1 3,2 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Trimethoprim TMP 0 0 0 0 0 0 0 0 0 0 3 9,7 0 0 1 3,2
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Enterococci - deviations
Lab code Strain_id Antimicrobial Read_value Exp_val Interp. Exp_interp
2 EURL ENT-10.7 Chloramphenicol CHL 32 64 S R
2 EURL ENT-10.8 Ampicillin AMP 8 4 R S
11 EURL ENT-10.7 Chloramphenicol CHL 32 64 S R
12 EURL ENT-10.7 Chloramphenicol CHL 32 64 S R
12 EURL ENT-10.8 Ampicillin AMP 8 4 R S
17 EURL ENT-10.5 Ampicillin AMP 4 4 R S
20 EURL ENT-10.5 Ampicillin AMP 8 4 R S
20 EURL ENT-10.5 Quinopristin-dalfopristin (Synercid) SYN 4 4 R S
20 EURL ENT-10.8 Quinopristin-dalfopristin (Synercid) SYN 4 4 R S
21 EURL ENT-10.7 Chloramphenicol CHL 32 64 S R
21 EURL ENT-10.8 Erythromycin ERY 128 > 128 S R
22 EURL ENT-10.7 Chloramphenicol CHL 32 64 S R
23 EURL ENT-10.7 Chloramphenicol CHL 32 64 S R
25 EURL ENT-10.7 Chloramphenicol CHL 32 64 S R
26 EURL ENT-10.7 Chloramphenicol CHL 32 64 S R
29 EURL ENT-10.7 Chloramphenicol CHL 32 64 S R
30 EURL ENT-10.7 Chloramphenicol CHL 32 64 S R
33 EURL ENT-10.8 Ampicillin AMP 8 4 R S
34 EURL ENT-10.7 Chloramphenicol CHL 32 64 S R
36 EURL ENT-10.7 Chloramphenicol CHL 32 64 S R
39 EURL ENT-10.6 Ciprofloxacin CIP 8 1 R S
40 EURL ENT-10.2 Erythromycin ERY > 8 <= 1 R S
40 EURL ENT-10.2 Gentamicin GEN > 1024 <= 8 R S
40 EURL ENT-10.2 Tetracycline TET 16 <= 1 R S
40 EURL ENT-10.3 Quinopristin-dalfopristin (Synercid) SYN 4 8 S R
40 EURL ENT-10.5 Chloramphenicol CHL > 32 8 R S
40 EURL ENT-10.5 Erythromycin ERY > 8 2 R S
40 EURL ENT-10.6 Gentamicin GEN <= 128 > 1024 S R
40 EURL ENT-10.6 Quinopristin-dalfopristin (Synercid) SYN 4 32 S -
40 EURL ENT-10.7 Gentamicin GEN 256 <= 8 R S
41 EURL ENT-10.4 Tigecycline TGC = 0.5 = 0.25 R S
41 EURL ENT-10.5 Ampicillin AMP 8 4 R S
41 EURL ENT-10.6 Tigecycline TGC = 0.5 = 0.25 R S
42 EURL ENT-10.5 Quinopristin-dalfopristin (Synercid) SYN 8 4 R S
42 EURL ENT-10.7 Chloramphenicol CHL 32 64 S R
42 EURL ENT-10.7 Teicoplanin TEI 64 <= 0.5 R S
42 EURL ENT-10.7 Vancomycin VAN > 128 2 R S
42 EURL ENT-10.8 Ampicillin AMP 8 4 R S
45 EURL ENT-10.4 Gentamicin GEN 32 256 S R
45 EURL ENT-10.4 Tigecycline TGC = 0.5 = 0.25 R S
45 EURL ENT-10.6 Gentamicin GEN 32 > 1024 S R
45 EURL ENT-10.6 Tigecycline TGC 1 = 0.25 R S
45 EURL ENT-10.7 Chloramphenicol CHL 32 64 S R
45 EURL ENT-10.7 Linezolid LZD 4 8 S R
45 EURL ENT-10.8 Ampicillin AMP 8 4 R S
56 EURL ENT-10.7 Chloramphenicol CHL 32 64 S R
60 EURL ENT-10.7 Chloramphenicol CHL 32 64 S R
Excluded from final rude (> 25% deviations)
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Staphylococcus aureus  - deviations
Lab. Code Strain_id Antibiotic_id Read_value Exp_val Interp. Exp_interp
2 EURL ST-10.8 Ciprofloxacin CIP =  2.0 1 R S
4 EURL ST-10.5 Sulfamethoxazole SMX > 512.0 128 R S
4 EURL ST-10.8 Ciprofloxacin CIP =  2.0 1 R S
11 EURL ST-10.8 Ciprofloxacin CIP =  2.0 1 R S
12 EURL ST-10.4 Ciprofloxacin CIP =  1.0 2 S R
17 EURL ST-10.2 Clindamycin CLN <=  0.12 16 S R
17 EURL ST-10.2 Erythromycin ERY =  0.5 > 16 S R
17 EURL ST-10.2 Quinopristin-dalfopristin (Synercid) SYN <=  0.5 8 S R
17 EURL ST-10.2 Tiamulin TIA =  1.0 > 32 S R
17 EURL ST-10.6 Clindamycin CLN =  0.25 > 256 S R
17 EURL ST-10.6 Erythromycin ERY =  0.5 > 16 S R
17 EURL ST-10.6 Quinopristin-dalfopristin (Synercid) SYN =  1.0 2 S R
17 EURL ST-10.6 Trimethoprim TMP <=  2.0 > 32 S R
19 EURL ST-10.4 Ciprofloxacin CIP =  1.0 2 S R
20 EURL ST-10.8 Ciprofloxacin CIP =  2.0 1 R S
21 EURL ST-10.4 Ciprofloxacin CIP =  1.0 2 S R
21 EURL ST-10.4 Sulfamethoxazole SMX =  128.0 > 512 S R
25 EURL ST-10.8 Sulfamethoxazole-Trimethoprim SXT =  0.5 1 S R
26 EURL ST-10.5 Sulfamethoxazole-Trimethoprim SXT =  0.5 1 S R
26 EURL ST-10.8 Sulfamethoxazole-Trimethoprim SXT =  0.25 1 S R
29 EURL ST-10.8 Ciprofloxacin CIP =  2.0 1 R S
30 EURL ST-10.4 Ciprofloxacin CIP =  1.0 2 S R
31 EURL ST-10.6 Tiamulin TIA <=  2.0 4 S R
31 EURL ST-10.8 Ciprofloxacin CIP > 1.0 1 R S
31 EURL ST-10.8 Sulfamethoxazole-Trimethoprim SXT <=  0.5 1 S R
33 EURL ST-10.4 Ciprofloxacin CIP =  1.0 2 S R
34 EURL ST-10.5 Quinopristin-dalfopristin (Synercid) SYN > 2.0 1 R S
34 EURL ST-10.5 Sulfamethoxazole-Trimethoprim SXT 1 S R
34 EURL ST-10.6 Sulfamethoxazole-Trimethoprim SXT 1 S R
34 EURL ST-10.8 Sulfamethoxazole-Trimethoprim SXT 1 S R
36 EURL ST-10.4 Ciprofloxacin CIP =  1.0 2 S R
36 EURL ST-10.6 Quinopristin-dalfopristin (Synercid) SYN =  1.0 2 S R
36 EURL ST-10.6 Tiamulin TIA =  2.0 4 S R
37 EURL ST-10.8 Ciprofloxacin CIP =  2.0 1 R S
39 EURL ST-10.4 Ciprofloxacin CIP =  1.0 2 S R
40 EURL ST-10.6 Cefoxitin FOX =  4.0 8 S R
40 EURL ST-10.6 Ciprofloxacin CIP =  1.0 > 8 S R
40 EURL ST-10.6 Clindamycin CLN =  0.25 > 256 S R
40 EURL ST-10.6 Erythromycin ERY =  1.0 > 16 S R
40 EURL ST-10.6 Gentamicin GEN <=  1.0 16 S R
40 EURL ST-10.6 Quinopristin-dalfopristin (Synercid) SYN <=  0.5 2 S R
40 EURL ST-10.6 Tiamulin TIA =  1.0 4 S R
40 EURL ST-10.7 Sulfamethoxazole SMX =  256.0 64 R S
40 EURL ST-10.8 Cefoxitin FOX =  16.0 4 R S
40 EURL ST-10.8 Ciprofloxacin CIP > 8.0 1 R S
40 EURL ST-10.8 Clindamycin CLN > 4.0 =  0.094 R S
40 EURL ST-10.8 Erythromycin ERY > 8.0 =  0.5 R S
40 EURL ST-10.8 Gentamicin GEN > 16.0 =  0.5 R S
40 EURL ST-10.8 Quinopristin-dalfopristin (Synercid) SYN =  2.0 <=  0.5 R S
40 EURL ST-10.8 Tiamulin TIA > 4.0 1 R S
41 EURL ST-10.4 Ciprofloxacin CIP =  1.0 2 S R
41 EURL ST-10.4 Gentamicin GEN =  2.0 > 16 S R
42 EURL ST-10.4 Ciprofloxacin CIP =  1.0 2 S R
42 EURL ST-10.8 Ciprofloxacin CIP =  2.0 1 R S
45 EURL ST-10.3 Tetracycline TET =  2.0 <=  0.5 R S
45 EURL ST-10.4 Trimethoprim TMP =  4.0 1 R S
45 EURL ST-10.4 Vancomycin VAN =  16.0 <=     1 R S
45 EURL ST-10.5 Quinopristin-dalfopristin (Synercid) SYN =  2.0 1 R S
45 EURL ST-10.5 Sulfamethoxazole SMX > 512.0 128 R S
45 EURL ST-10.7 Sulfamethoxazole SMX =  512.0 64 R S
45 EURL ST-10.7 Tetracycline TET =  2.0 <=  0.5 R S
45 EURL ST-10.7 Trimethoprim TMP =  4.0 2 R S
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45 EURL ST-10.8 Ciprofloxacin CIP =  2.0 1 R S
56 EURL ST-10.4 Ciprofloxacin CIP =  1.0 2 S R
56 EURL ST-10.6 Quinopristin-dalfopristin (Synercid) SYN =  1.0 2 S R
56 EURL ST-10.6 Tiamulin TIA =  2.0 4 S R
59 EURL ST-10.4 Ciprofloxacin CIP =  1.0 2 S R
Excluded from final report (> 25% deviations)
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Escherichia coli - deviations
Lab. code Panel Strain_id Antibiotic_id Read_value Exp_val Interp. Exp_interp
2 2 EURL EC-10.8 Ertapenem ETP = 0.06 =  0.12 S R
4 2 EURL EC-10.1 Cefepime FEP = 0.25 =  0.25 S R
4 2 EURL EC-10.3 Cefepime FEP = 0.06 =  0.25 S R
4 2 EURL EC-10.4 Cefepime FEP = 0.25 =  0.25 S R
4 1 EURL EC-10.5 Sulfamethoxazole SMX 128 16 R S
4 2 EURL EC-10.8 Cefepime FEP = 0.25 =  0.25 S R
4 1 EURL EC-10.8 Ciprofloxacin CIP = 0.12 =  0.03 R S
4 2 EURL EC-10.8 Ertapenem ETP = 0.03 =  0.12 S R
4 1 EURL EC-10.8 Sulfamethoxazole SMX > 1024 32 R S
4 1 EURL EC-10.8 Trimethoprim TMP 4 <=  0.25 R S
6 2 EURL EC-10.4 Cefoxitin FOX 16 2 R S
11 2 EURL EC-10.8 Ertapenem ETP = 0.06 =  0.12 S R
16 2 EURL EC-10.8 Ertapenem ETP = 0.06 =  0.12 S R
18 1 EURL EC-10.8 Sulfamethoxazole SMX > 1024 32 R S
18 1 EURL EC-10.8 Tetracycline TET 16 4 R S
19 1 EURL EC-10.6 Trimethoprim TMP <= 0.25 > 32 S R
21 2 EURL EC-10.3 Cefepime FEP = 0.5 =  0.25 S R
22 2 EURL EC-10.8 Ertapenem ETP = 0.06 =  0.12 S R
23 2 EURL EC-10.1 Ertapenem ETP = 0.12 =  0.06 R S
25 2 EURL EC-10.8 Ertapenem ETP = 0.06 =  0.12 S R
26 1 EURL EC-10.1 Colistin COL 2 8 S R
26 1 EURL EC-10.3 Chloramphenicol CHL 16 32 S R
26 1 EURL EC-10.3 Colistin COL 2 4 S R
26 1 EURL EC-10.4 Chloramphenicol CHL 16 32 S R
26 2 EURL EC-10.8 Ertapenem ETP = 0.06 =  0.12 S R
29 1 EURL EC-10.3 Colistin COL 2 4 S R
29 2 EURL EC-10.8 Ertapenem ETP <= 0.06 =  0.12 S R
30 1 EURL EC-10.2 Tetracycline TET > 64 <=     2 R S
30 2 EURL EC-10.8 Ertapenem ETP = 0.06 =  0.12 S R
33 1 EURL EC-10.6 Trimethoprim TMP <= 0.25 > 32 S R
33 2 EURL EC-10.8 Ertapenem ETP = 0.06 =  0.12 S R
34 2 EURL EC-10.1 Cefepime FEP = 0.12 =  0.25 S R
34 2 EURL EC-10.2 Ceftazidime TAZ 2 2 S R
34 2 EURL EC-10.8 Ertapenem ETP = 0.06 =  0.12 S R
36 2 EURL EC-10.8 Ertapenem ETP  0.06 =  0.12 S R
37 1 EURL EC-10.6 Cefotaxime FOT <= 0.25 <=  0.25 R S
39 2 EURL EC-10.8 Ertapenem ETP  0.06 =  0.12 S R
40 1 EURL EC-10.1 Azithromycin AZI 32 8 R S
40 2 EURL EC-10.3 Cefepime FEP <= 0.06 =  0.25 S R
40 2 EURL EC-10.4 Cefepime FEP <= 0.06 =  0.25 S R
40 1 EURL EC-10.5 Sulfamethoxazole SMX > 1024 16 R S
40 2 EURL EC-10.8 Ertapenem ETP <= 0.015 =  0.12 S R
40 1 EURL EC-10.8 Sulfamethoxazole SMX 256 32 R S
42 1 EURL EC-10.3 Tetracycline TET 64 64 S R
42 2 EURL EC-10.5 Ertapenem ETP = 0.25 =  0.5 S R
42 1 EURL EC-10.6 Trimethoprim TMP = 0.5 > 32 S R
42 2 EURL EC-10.8 Ertapenem ETP = 0.06 =  0.12 S R
45 2 EURL EC-10.3 Cefoxitin FOX 8 4 R S
45 1 EURL EC-10.8 Sulfamethoxazole SMX 1024 32 R S
56 1 EURL EC-10.3 Colistin COL 2 4 S R
56 2 EURL EC-10.8 Ertapenem ETP = 0.06 =  0.12 S R
59 2 EURL EC-10.8 Ertapenem ETP = 0.06 =  0.12 S R
60 1 EURL EC-10.1 Tigecycline TGC > 8 =  0.5 R S
Excluded from final report (> 25% deviations)
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